Document:

<Page>
                                                                    Exhibit 10.2

                          CUBIST PHARMACEUTICALS, INC.

                        2002 DIRECTORS' STOCK OPTION PLAN

     The options granted under this 2002 Directors' Stock Option Plan are NOT
intended to be treated as "incentive stock options" within the meaning of
Section 422 of the Code.

     1.    DEFINITIONS. As used in this 2002 Directors' Stock Option Plan of
Cubist Pharmaceuticals, Inc., the following terms shall have the following
meanings:

     1.1.  ACCELERATE, ACCELERATED, and ACCELERATION, means that as of the
relevant time of reference such Option will become exercisable with respect to
some or all of the shares of Stock for which it was not then otherwise
exercisable by its terms.

     1.2.  BOARD means the Company's Board of Directors.

     1.3.  CHANGE IN CORPORATE CONTROL means (1) the closing of (A) any
consolidation or merger of the Company in which the Company is not the
continuing or surviving corporation or pursuant to which Shares would be
converted into cash, securities or other property, other than a merger or
consolidation which the holders of Stock immediately prior to the merger or
consolidation will have the same proportionate ownership of common stock of the
surviving corporation immediately after the merger or consolidation as before
the merger or consolidation, or (B) any sale, lease, exchange, or other transfer
in a single transaction or a series of related transactions of all or
substantially all of the assets of the Company, or (2) the date on which any
"person" (as defined in Section 13(d) of the Exchange Act), other than the
Company or a Subsidiary or employee benefit plan or trust maintained by the
Company or any of its Subsidiaries shall become (together with its "affiliates"
and "associates," as defined in Rule 12b-2 under the Exchange Act) the
"beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly
or indirectly, of 100% of the Stock outstanding at the time, with the prior
approval of the Board, or (3) a Hostile Change in Corporate Control.

     1.4.  CODE means the United States Internal Revenue Code of 1986, as
amended.

<Page>
                                       -2-

     1.5.  COMPANY Means Cubist Pharmaceuticals, Inc., a Delaware corporation.

     1.6.  COMPENSATION COMMITTEE Means a committee comprised of two or more
Outside Directors, appointed by the Board, and vested by the Board with the
power and authority to administer the Plan in accordance with the provisions of
Section 5.

     1.7.  EXCHANGE ACT Means the Securities Exchange Act of 1934, as amended.

     1.8.  ELIGIBLE DIRECTOR Means a director of one or more of the Company and
its Subsidiaries who is not also an employee or officer of one or more of the
Company and its Subsidiaries.

     1.9.  FAIR MARKET VALUE Means on any date (i) if the Stock is traded on a
stock exchange or on the Nasdaq National Market, the closing price on the date
in question or, if no trades were reported on such date, the closing price on
the most recent trading day preceding such date on which a trade occurred, and
(ii) if the Stock is not traded on a stock exchange or on the Nasdaq National
Market, the value of a Share on such date as determined by the Board or the
Compensation Committee.

     1.10. GRANT DATE Means the date as of which an Option is granted.

     1.11. HOLDER Means, with respect to any Option, (i) the Optionee to whom
such Option shall have been granted under the Plan, or (ii) any transferee of
such Option to whom such Option shall have been transferred in accordance with
the provisions of Section 13.

     1.12. HOSTILE CHANGE IN CORPORATE CONTROL means the date on which any
"person" (as defined in Section 13(d) of the Exchange Act), other than the
Company or a Subsidiary or employee benefit plan or trust maintained by the
Company or any of its Subsidiaries shall become (together with its "affiliates"
and "associates," as defined in Rule 12b-2 under the Exchange Act) the
"beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly
or indirectly, of more than 25% of the Stock outstanding at the time, without
the prior approval of the Board.

     1.13. INCENTIVE OPTION means an "incentive stock option" within the meaning
of Section 422 of the Code.

     1.14. INCUMBENT DIRECTORS Means, in the case of a Hostile Change in

<Page>
                                       -3-

Corporate Control, those individuals who were members of the Company's Board of
Directors immediately prior to such Hostile Change in Corporate Control.

     1.15. OPTION Means an option granted under the Plan to purchase Shares.

     1.16. OPTION AGREEMENT Means an agreement between the Company and an
Optionee, setting forth the terms and conditions of an Option.

     1.17. OPTION PRICE means the price paid by an Optionee for a Share upon
exercise of an Option.

     1.18. OPTIONEE Means a person eligible to receive an Option, to whom an
Option shall have been granted under the Plan.

     1.19. OUTSIDE DIRECTOR Shall mean a member of the Board who is not an
officer, employee or consultant of the Company or any Subsidiary.

     1.20. PLAN means this 2002 Directors' Stock Option Plan of the Company, as
amended from time to time.

     1.21. SECURITIES ACT Means the United States Securities Act of 1933, as
amended.

     1.22. SHARES Means shares of Stock.

     1.23. STOCK means common stock, $.001 par value per share, of the Company.

     1.24. SUBSIDIARY Means any corporation which qualifies as a subsidiary of
the Company under the definition of "subsidiary corporation" in Section 424(f)
of the Code.

     2.    PURPOSE. This Plan is intended to promote the recruiting and
retention of highly qualified Eligible Directors, to strengthen commonality of
interest between directors and stockholders by encouraging ownership of Stock by
Eligible Directors, and to provide additional incentives for Eligible Directors
to promote the success of the Company's business. The Plan is NOT intended to be
an incentive stock option plan within the meaning of Section 422 of the Code.
None of the Options granted hereunder will be Incentive Options.

<Page>
                                       -4-

     3.    TERM OF THE PLAN. Options may be granted hereunder at any time in the
period commencing upon the effectiveness of the Plan pursuant to Section 19 and
ending on June 30, 2012.

     4.    STOCK SUBJECT TO tHE PLAN. Subject to the provisions of Section 14 of
the Plan, at no time shall the number of Shares then outstanding which are
attributable to the exercise of Options granted under the Plan, PLUS the number
of Shares then issuable upon exercise of outstanding Options granted under the
Plan exceed 175,000 Shares. The shares of Stock to be issued under the Plan,
will be made available, at the discretion of the Compensation Committee, from
authorized but unissued Shares or Shares held by the Company in its treasury. If
any Option expires, terminates or is cancelled for any reason without having
been exercised in full, the Shares not purchased by the Optionee shall again be
available for Options to be granted under the Plan.

     5.    ADMINISTRATION. The Plan shall be administered by the Compensation
Committee. Subject to the provisions of the Plan, the Compensation Committee
shall have complete authority to interpret the Plan, to prescribe, amend and
rescind rules and regulations relating to it, to determine the terms and
provisions of the respective Option Agreements (which need not be identical),
and to make all other determinations necessary or advisable for the
administration of the Plan. The Compensation Committee's determinations on the
matters referred to in this Section 5 shall be final, binding and conclusive on
all persons having or claiming an interest under the Plan or an Option made
pursuant hereto. Notwithstanding anything expressed or implied in the Plan to
the contrary, at any time and on any one or more occasions, the Board may itself
exercise any of the powers and responsibilities assigned the Compensation
Committee under the Plan and when so acting shall have the benefit of all of the
provisions of this Plan pertaining to the Compensation Committee's exercise of
its authorities hereunder.

     6.    ELIGIBILITY. Only Eligible Directors shall be granted Options under
the Plan.

<Page>
                                       -5-

     7.    OPTIONS.

     7.1.  DIRECTORS ELECTED FOR FIRST TIME. Subject to the Plan's effectiveness
as set forth in Section 19, each Eligible Director who is elected to the Board
during the term of the Plan (whether elected at an annual or special
stockholders' meeting or by action of the Board or written consent of
stockholders without a meeting), and who prior to such election was never
previously a member of the Board, shall be granted, on the date of such meeting
or other appointment, an Option to purchase 15,000 Shares. Subject to Sections
9, 10 and 11, grants of Options under this Section 7.1 occur automatically
without any action being required of the Optionee, the Compensation Committee,
the Board, the Company or any other person, entity or body.

     7.2.  ANNUAL GRANTS. Subject to the Plan's effectiveness as set forth in
Section 19, on the date of each annual meeting of stockholders of the Company
commencing with the 2003 Annual Meeting of Stockholders of the Company, each
Eligible Director who continues to be a director of the Company as of the close
of business on the date of such annual meeting of stockholders shall be granted
an Option on such business day, to purchase 10,000 Shares. Subject to Sections
9, 10 and 11, grants of Options under this Section 7.2 occur automatically
without any action being required of the Optionee, the Compensation Committee,
the Board, the Company or any other person, entity or body.

     7.3.  CERTAIN TERMS OF OPTIONS. Each Option granted to an Optionee under
this Section 7 shall have an exercise price equal to 100% of the Fair Market
Value of the Stock on the applicable Grant Date. No Option granted pursuant to
this Section 7 is intended to qualify as an incentive stock option within the
meaning of Section 422 of the Code. The grants shall be evidenced by Option
Agreements containing provisions that are in all respects consistent with this
Section 7. All of such Option Agreements shall contain identical terms and
conditions, except as otherwise required or permitted by this Section 7.

     7.4.  OPTION PERIOD. The option period for any Option granted pursuant to
this Section 7 shall be ten years from the date of grant.

     7.5.  EXERCISABILITY. Each Option granted to an Eligible Director pursuant
to Section 7.1 hereof (a "SECTION 7.1 OPTION") shall become exercisable in
twelve (12) equal quarterly installments, with the first installment becoming
exercisable on the last day of the first full fiscal quarter following the Grant
Date applicable to such Section 7.1 Option and

<Page>
                                       -6-

an additional installment becoming exercisable on the last day of each of the
eleven successive fiscal quarters following such first fiscal quarter; PROVIDED,
HOWEVER, that if the Optionee with respect to such Section 7.1 Option shall
cease to be a director of the Company, then, notwithstanding anything in this
Section 7.5 to the contrary and subject to Sections 7.6 and 12 hereof, such
Section 7.1 Option shall thereafter be exercisable only with respect to those of
such installments for which such Section 7.1 Option is exercisable, pursuant to
this Section 7.5, at the time of such cessation. Each Option granted to an
Eligible Director pursuant to Section 7.2 hereof (a "SECTION 7.2 OPTION") shall
be exercisable according to a schedule determined by the Board in its sole
discretion (and not the Compensation Committee, notwithstanding the
responsibilities assigned to the Compensation Committee pursuant to Section 5),
PROVIDED, HOWEVER, that if the Optionee with respect to such Section 7.2 Option
shall cease to be a director of the Company, then, subject to Sections 7.6 and
12 hereof, such Section 7.2 Option shall thereafter be exercisable only with
respect to those of such installments for which such Section 7.2 Option is
exercisable, pursuant to this Section 7.5, at the time of such cessation.

     7.6.  CERTAIN MODIFICATIONS OF OPTIONS. Notwithstanding anything in this
Section 7 or any applicable Option Agreement to the contrary, in the case of an
Option not otherwise immediately exercisable in full, the Compensation Committee
may accelerate the exercisability of such Option in whole or in part at any
time. In the event that the Committee accelerates the exercisability of any
Option in whole or in part at any time, the Compensation Committee may require
as a condition precedent to the effectiveness of any such acceleration that the
holder of such Option shall enter into a written agreement with the Company
providing, among other things, that the Shares subject to such Option shall,
following their issuance upon exercise of such Option, be subject to a
repurchase option in favor of the Company upon such terms as the Compensation
Committee shall determine in its sole and absolute discretion.

     8.    EXERCISE OF OPTION.

           (a) An Option may be exercised only by giving written notice, in the
manner provided in Section 18 hereof, specifying the number of Shares as to
which the Option is being exercised, accompanied (except as otherwise provided
in paragraphs (b) and (c) of this Section 8) by full payment for such Shares in
the form of a check or bank draft payable to the order of the Company or other
Shares with a current Fair Market Value equal to the Option Price of the Shares
to be purchased. Receipt by the Company of such notice and payment shall
constitute the exercise of the

<Page>
                                       -7-

Option or a part thereof. Subject to the provisions of the Plan (including,
without limitation, Sections 9, 10 and 11) or any applicable Option Agreement,
within 30 days after receipt of such notice and payment, the Company shall
deliver or cause to be delivered to the Holder a certificate or certificates for
the number of Shares then being purchased by the Holder. Such Shares shall be
fully paid and nonassessable.

           (b) In lieu of payment by check, bank draft or other Shares
accompanying the written notice of exercise as described in paragraph (a) of
this Section 8, a Holder may, unless prohibited by applicable law, elect to
effect payment by including with the written notice referred to in paragraph (a)
of this Section 8 irrevocable instructions to deliver for sale to a registered
securities broker acceptable to the Company that number of Shares subject to the
Option being exercised sufficient, after brokerage commissions, to cover the
aggregate exercise price of such Option and, if the Holder further elects, the
withholding obligations of the Optionee and/or such Holder pursuant to Section
11 with respect to such exercise, together with irrevocable instructions to such
broker to sell such Shares and to remit directly to the Company such aggregate
exercise price and, if the Holder has so elected, the amount of such withholding
obligation. The Company shall not be required to deliver to such securities
broker any stock certificate for such Shares until it has received from the
broker such exercise price and, if the Holder has so elected, the amount of such
withholding obligation.

           (c) The Compensation Committee shall have complete authority, in its
discretion, to permit the Holder, in lieu of payment by check, bank draft or
other Shares accompanying the written notice of exercise as described in
paragraph (a) of this Section 8, to effect payment by executing and delivering
to the Company a promissory note in the aggregate principal amount of the Option
Price of the Shares to be purchased. The promissory note shall be upon the terms
and conditions (including, without limitation, collateral security) acceptable
to the Compensation Committee.

           (d) The right of the Holder to exercise an Option pursuant to any
provision of this Section 8, and the obligation of the Company to issue Shares
upon any exercise of an Option pursuant to this Section 8, is subject to
compliance with all of the other provisions of the Plan (including, without
limitation, Sections 9, 10 and 11) or any applicable Option Agreement.

     9.    RESTRICTIONS ON ISSUE OF SHARES.

           (a) Notwithstanding any other provision of the Plan, if, at any time,
in the reasonable opinion of the Company the issuance of Shares

<Page>
                                       -8-

covered by the exercise of any Option may constitute a violation of law, then
the Company may delay such issuance and the delivery of a certificate for such
Shares until (i) approval shall have been obtained from such governmental
agencies, other than the Securities and Exchange Commission, as may be required
under any applicable law, rule, or regulation; and (ii) in the case where such
issuance would constitute a violation of a law administered by or a regulation
of the Securities and Exchange Commission, one of the following conditions shall
have been satisfied:

     (1)   the Shares with respect to which such Option has been exercised are
at the time of the issue of such Shares effectively registered under the
Securities Act; or

     (2)   the Company shall have determined, on such basis as it deems
appropriate (including an opinion of counsel or a no-action letter, each in form
and substance reasonably satisfactory to the Company) that the sale, transfer,
assignment, pledge, encumbrance or other disposition of such shares or such
beneficial interest, as the case may be, does not require registration under the
Securities Act or any applicable state securities laws.

The Company shall make all reasonable efforts to bring about the occurrence of
said events.

     (b)   If the Company shall deem it necessary or desirable to register under
the Securities Act or other applicable statutes any Shares with respect to which
an Option shall have been granted, or to qualify any such Shares for exemption
from the Securities Act or other applicable statutes, then the Company shall
take such action at its own expense. The Company may require from each Holder,
such information in writing for use in any registration statement, prospectus,
preliminary prospectus or offering circular as is reasonably necessary for such
purpose and may require reasonable indemnity to the Company and its officers and
directors from such holder against all losses, claims, damage and liabilities
arising from such use of the information so furnished and caused by any untrue
statement of any material fact therein or caused by the omission to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances under which they were
made.

     (c)   All certificates for shares of Stock or other securities delivered
under the Plan shall be subject to such stop-transfer orders and other
restrictions as the Compensation Committee may deem advisable under the

<Page>
                                       -9-

rules, regulations, and other requirements of any stock exchange upon which the
Stock is then listed, and any applicable federal or state securities law, and
the Compensation Committee may cause a legend or legends to be put on any such
certificates to make appropriate reference to such restrictions.

     10.   PURCHASE FOR INVESTMENT.

     (a)   Without limiting the generality of Section 9 hereof, if the Shares to
be issued upon exercise of an Option granted under the Plan have not been
effectively registered under the Securities Act, the Company shall be under no
obligation to issue any Shares covered by any Option unless the person who
exercises such Option, in whole or in part, shall have made such written
representations and covenants to the Company (upon which the Company believes it
may reasonably rely) as the Company may deem necessary or appropriate for
purposes of ensuring that the issuance of such Shares will be exempt from the
registration requirements of the Securities Act and any applicable state
securities laws and otherwise in compliance with all applicable laws, rules and
regulations, including but not limited to written representations that the
Optionee is acquiring the shares for his or her own account for the purpose of
investment and not with a view to, or for sale in connection with, the
distribution of any such Shares.

     (b)   Each Share to be issued pursuant to Options granted pursuant to this
Plan may bear a reference to the investment representation made in accordance
with this Section 10 and to the fact that no registration statement has been
filed with the Securities and Exchange Commission in respect to such Shares of
Stock.

     11.   WITHHOLDING; NOTICE OF DISPOSITION OF STOCK PRIOR TO EXPIRATION OF
SPECIFIED HOLDING PERIOD.

           (a) Whenever Shares are to be issued in satisfaction of an Option
granted hereunder, the Company shall have the right to require the Optionee
and/or any subsequent Holder to remit to the Company an amount sufficient to
satisfy federal, state, local, employment or other tax withholding requirements
if, when and to the extent required by law (whether so required to secure for
the Company an otherwise available tax deduction or otherwise) prior to the
delivery of any certificate or certificates for such Shares. The obligations of
the Company under the Plan shall be conditional on such payment and the Company
shall, to the extent permitted by law, have the right to deduct any such taxes
from any payment of any kind otherwise due to the recipient of an Award.

<Page>
                                      -10-

           (b) The Compensation Committee may, at or after grant, permit an
Optionee and/or subsequent Holder to satisfy any tax withholding requirements
pertaining to the exercise of an Option by delivery to the Company of Shares
(including, without limitation, Shares retained from the Option exercise that is
creating the tax obligation) having a value equal to the amount to be withheld.
The value of Shares to be so delivered shall be based on the Compensation
Committee's determination of the Fair Market Value of a Share on the date the
amount of tax to be withheld is to be determined.

     12.   TERMINATION OF ASSOCIATION WITH THE COMPANY. If an Optionee ceases to
be a director of the Company, and if applicable, its Subsidiaries, for any
reason other than death of such Optionee, any Option held by such Optionee
and/or any subsequent Holder may be exercised by such Optionee and/or such
subsequent Holder at any time within 90 days after the termination of such
relationship, but only to the extent exercisable at termination and in no event
after the applicable option period. If an Optionee dies, any Option held by such
Optionee and/or any subsequent Holder may be exercised by such Optionee, such
subsequent Holder and/or the executor or administrator of such Optionee or such
subsequent Holder at any time within the shorter of the applicable option period
or 12 months after the date of the Optionee's death, but only to the extent
exercisable at the time of such Optionee's death. Options which are not
exercisable at the time of termination between the Company and the Optionee or
which are so exercisable but are not exercised within the time periods described
above shall terminate. Notwithstanding the foregoing, in the event that (i) the
applicable Option Agreement with respect to an Option shall contain specific
provisions governing the effect that any such termination shall have on the
exercisability of such Option, or (ii) the Board, shall at any time adopt
specific provisions governing the effect that any such termination shall have on
the exercisability of such Option, then such provisions shall, to the extent
that they are inconsistent with the provisions of this Section 12, control and
be deemed to supersede the provisions of this Section 12.

     13.   TRANSFERABILITY OF OPTIONS. Options shall not be transferable;
PROVIDED, HOWEVER, that Options shall be transferable by will or the laws of
descent and distribution; and PROVIDED, FURTHER, that Options may be transferred
to a third party if and to the extent authorized and permitted by the
Compensation Committee at the time of grant of such Options or at any time
thereafter. In granting its authorization and permission to any proposed
transfer of an Option to a third party, the Compensation Committee may impose
conditions or requirements that must be satisfied by

<Page>
                                      -11-

the transferor or the third party transferee prior to or in connection with such
transfer, including, without limitation, any conditions or requirements that may
be necessary or desirable, in the sole and absolute discretion of the
Compensation Committee, to ensure that such proposed transfer complies with
applicable securities laws or to prevent the Company, such transferor or such
third party transferee from violating or otherwise not be in compliance with
applicable securities laws as a result of such transfer. The Compensation
Committee may at any time and from time to time delegate to one or more officers
of the Company the authority to permit transfers of Options to third parties
pursuant to this Section 13, which authorization shall be exercised by such
officer or officers in accordance with guidelines established by the
Compensation Committee at any time and from time to time.. The restrictions on
transferability set forth in this Section 13 shall in no way preclude any Holder
from effecting "cashless" exercises of an Option pursuant to, and in accordance
with, Section 8(b) hereof.

     14.   ADJUSTMENT PROVISIONS.

     14.1  ADJUSTMENT FOR CORPORATE ACTIONS. All of the share numbers set forth
in the Plan reflect the capital structure of the Company as of March 5, 2002. If
subsequent to such date the outstanding shares of Common Stock (or any other
securities covered by the Plan by reason of the prior application of this
Section) are increased, decreased, or exchanged for a different number or kind
of shares or other securities or property (including cash), or if subsequent to
such date additional shares or new or different shares or other securities or
property (including cash) are distributed with respect to or in exchange for
shares of Common Stock or other securities upon the merger, consolidation, sale
of all or substantially all the property or assets of the Company, sale of all
of the outstanding Common Stock of the Company, reorganization,
recapitalization, reclassification, stock dividend, stock split, reverse stock
split, or other distribution with respect to shares of Common Stock, or other
securities, (each of the foregoing events an "ADJUSTMENT EVENT") an appropriate
and proportionate adjustment will be made in (i) the maximum number and kind of
shares or other securities subject to the provisions of Section 4, (ii) the
numbers and kinds of shares or other securities or property (including cash)
subject to the then outstanding Options, and (iii) the exercise price for each
share or other unit of any other securities subject to then outstanding Options
(without change in the aggregate purchase price as to which such Options remain
exercisable). Without limiting the generality of the foregoing provisions of
this Section 14.1, upon the occurrence of an Adjustment Event, Holders of
Options outstanding immediately prior to such Adjustment Event shall

<Page>
                                      -12-

upon exercise of such Options at any time following such Adjustment Event be
entitled to receive the shares of stock, other securities or property (including
cash) that such Holders would have received as a result of such Adjustment Event
if such Holders had exercised such Options immediately prior to such Adjustment
Event. The provisions of this Section 14.1 (including, without limitation, the
immediately preceding sentence) shall apply successively with respect to
multiple Adjustment Events that occur over time.

     14.2  CHANGE IN CORPORATE CONTROL. Subject to any provisions of then
outstanding Options granting greater rights to the holders thereof, in the event
of a Change in Corporate Control any then outstanding Options shall Accelerate.
For the purposes of the preceding sentence, (i) in the case of a Change in
Corporate Control that is not a Hostile Change in Corporate Control, the Board
(and not the Compensation Committee, notwithstanding the responsibilities
assigned to the Compensation Committee pursuant to Section 5) shall have the
discretion to exclude any such Change in Corporate Control from the application
of the provisions of the immediately preceding sentence, and (ii) in the case of
a Hostile Change in Corporate Control, a majority of the Incumbent Directors
prior to such Hostile Change in Corporate Control shall have the discretion to
exclude any such Change in Corporate Control from the application of the
provisions of the immediately preceding sentence. To the extent Options are not
assumed, substituted or replaced upon a Change in Corporate Control that is not
a Hostile Change in Corporate Control, the Board (and not the Compensation
Committee, notwithstanding the responsibilities assigned to the Compensation
Committee pursuant to Section 5) shall have the discretion to terminate such
outstanding Options to the extent not exercised prior to or simultaneously with
such Change in Corporate Control. Upon a Change in Corporate Control, each
outstanding Option will be appropriately adjusted simultaneously with such
Change in Corporate Control in accordance with Section 14.1.

     14.3  DISSOLUTION OR LIQUIDATION. Upon dissolution or liquidation of the
Company each outstanding Option shall terminate, but the Optionee (if at the
time in the employ of or otherwise associated with the Company or any of its
Subsidiaries) shall have the right, immediately prior to such dissolution or
liquidation, to exercise the Option to the extent exercisable on the date of
such dissolution or liquidation.

     14.4  RELATED MATTERS. Any adjustment in Options made pursuant to this
Section 14 shall be determined and made, if at all, by the Compensation
Committee and shall include any correlative modification of

<Page>
                                      -13-

terms, including of Option Prices, which the Compensation Committee may deem
necessary or appropriate so as to ensure the rights of the Holders are not
substantially diminished nor enlarged as a result of the adjustment and
corporate action other than as expressly contemplated in this Section 14. No
fraction of a share shall be purchasable or deliverable upon exercise, but in
the event any adjustment hereunder of the number of shares covered by an Option
shall cause such number to include a fraction of a share, such number of shares
shall be adjusted to the nearest smaller whole number of shares.

     15.   RESERVATION OF STOCK. The Company shall at all times during the term
of the Plan and, without duplication, of any outstanding Options reserve or
otherwise keep available such number of Shares as will be sufficient to satisfy
the requirements of the Plan (if not then terminated) and such outstanding
Options and shall pay all fees and expenses necessarily incurred by the Company
in connection therewith.

     16.   LIMITATION OF RIGHTS IN STOCK; NO SPECIAL EMPLOYMENT OR OTHER RIGHTS.
A Holder shall not be deemed for any purpose to be a stockholder of the Company
with respect to any of the Shares covered by an Option, except to the extent
that the Option shall have been exercised with respect thereto and, in addition,
a certificate shall have been issued therefor and delivered to the Holder or his
agent. Any Stock issued pursuant to the Option shall be subject to all
restrictions upon the transfer thereof which may be now or hereafter imposed by
the Certificate of Incorporation, and the By-laws of the Company, if any.
Nothing contained in the Plan or in any Option shall confer upon any Optionee
any right with respect to the continuation of his or her retention as a director
to the Company (or any Subsidiary), or interfere in any way with the right of
the Company (or any Subsidiary), subject to the terms of any separate employment
or consulting agreement or provision of law or corporate articles or by-laws to
the contrary, at any time to terminate such directorship or to increase or
decrease the compensation of the Optionee from the rate in existence at the time
of the grant of an Option.

     17.   TERMINATION AND AMENDMENT OF THE PLAN. The Board may at any time
terminate the Plan or make such modifications of the Plan as it shall deem
advisable. Any termination of the Plan shall not affect the terms of any Option
outstanding on the date of such termination. Unless the Board otherwise
expressly provides and except to the extent otherwise provided in the next
sentence, amendments of the Plan shall apply to all Options outstanding on the
date of such amendments to the same extent as if such amendments had been in
effect at the time that each of such outstanding

<Page>
                                      -14-

Options were granted. Notwithstanding the foregoing, no amendment of the Plan
may, without the consent of any recipient of an Option outstanding on the date
of such amendment, (i) reduce the number of shares of Stock subject to such
Option, (ii) increase the Option Price of such Option, or (iii) change the
vesting schedule of such Option in a manner that adversely affects the rights of
the Optionee. The Compensation Committee may amend the terms of any Option
theretofore granted, prospectively or retroactively, PROVIDED that the Option as
amended is consistent with the terms of the Plan, and PROVIDED, FURTHER, that no
such amendment of such Option may, without the consent of any Optionee, (x)
reduce the number of shares of Stock subject to such Option, (y) increase the
Option Price, or (z) change the vesting schedule of such Option in a manner that
adversely affects the rights of the recipient under such Option.

     18.   NOTICES AND OTHER COMMUNICATIONS. All notices and other
communications required or permitted under the Plan shall be effective if in
writing and if delivered or sent by certified or registered mail, return receipt
requested (a) if to the Holder, at his or her residence address last filed with
the Company, and (b) if to the Company, at 65 Hayden Avenue, Lexington,
Massachusetts 02421, Attention: General Counsel or to such other persons or
addresses as the Holder or the Company may specify by a written notice to the
other from time to time. Copies of all notices sent to any Holder that is not
the Optionee shall also be sent to the Optionee in the manner set forth in this
Section 18.

     19.   EFFECTIVENESS. This 2002 Directors' Stock Option Plan was approved by
the Board on March 5, 2002, and the Plan was ratified and approved by the
stockholders of the Company on June 13, 2002.<Page>

                                                                    EXHIBIT 10.3

                             CONFIDENTIAL TREATMENT

                                LICENSE AGREEMENT

     This LICENSE AGREEMENT (this "AGREEMENT") effective as of July 31, 2002
(the "EFFECTIVE DATE"), is between CUBIST PHARMACEUTICALS, INC., a corporation
organized and existing under the laws of Delaware (together with its Affiliates
(as defined below) referred to herein as "CUBIST") and BIOCHEMIE GMBH, a
corporation organized and existing under the laws of Austria (together with its
Affiliates referred to herein as "BIOCHEMIE"). BIOCHEMIE and CUBIST are
sometimes hereinafter referred to each as a "Party" and collectively as the
"Parties."

                                   WITNESSETH:

     WHEREAS, BIOCHEMIE has developed a proprietary compound known as CAB-175
using BIOCHEMIE Know-How (as defined below) and has rights to BIOCHEMIE Patent
Rights (as defined below); and

     WHEREAS, CUBIST desires to obtain a license under the BIOCHEMIE Patent
Rights and BIOCHEMIE Know-How upon the terms and conditions set forth herein for
purposes of developing and commercializing CAB-175 and certain other compounds
in the Territory (as defined below), and BIOCHEMIE desires to grant such a
license.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, the Parties hereby agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

     Unless specifically set forth to the contrary herein, the following terms,
whether used in the singular or plural, shall have the respective meanings set
forth below:

1.1      "Abandoned Product" shall have the meaning set forth in Section 3.5(b).

1.2      "Affiliate" shall mean, with respect to any Person, (i) any other
         Person of which fifty percent (50%) or more of the securities or other
         ownership interests representing the equity, the voting stock or
         general partnership interest are owned, controlled, or held, directly
         or indirectly by, or under common ownership or control with, such
         Person; or (ii) any other Person that, directly or indirectly, owns,
         controls, or holds fifty percent (50%) or more of the securities or
         other ownership interests representing the equity, the voting stock or,
         if applicable, the general partnership interest, of such Person.

<Page>

                                       -2-

1.3      "Agreement" shall have the meaning set forth in the preamble.

1.4      "BIOCHEMIE  Improvement"  shall mean any improvement or enhancement
         in or to (i) the manufacture, formulation, ingredients, preparation,
         presentation, means of delivery, dosage or packaging of Licensed
         Products or (ii) any invention that is necessary or useful in
         connection with the research, development, manufacture, marketing,
         promotion, use, sale, import or export of Licensed Products, which
         improvement or enhancement is owned or licensed by BIOCHEMIE at any
         time during the term of this Agreement.

1.5      "BIOCHEMIE Indemnitees" shall have the meaning set forth in Section
         7.2.1.

1.6      "BIOCHEMIE Inventions" shall have the meaning set forth in Section
         8.1.

1.7      "BIOCHEMIE Joint Patent Rights" shall mean all of BIOCHEMIE's
         right, title and interest in and to the Joint Patents.

1.8      "BIOCHEMIE Know-How" shall mean all information and materials
         including, but not limited to, discoveries, BIOCHEMIE Improvements,
         processes, formulas, data, inventions, know-how and trade secrets,
         patentable or otherwise, that (i) at any time during the term of this
         Agreement are owned by BIOCHEMIE or that BIOCHEMIE, through license or
         otherwise, has or acquires rights, in each case that are capable of
         being licensed or sublicensed to CUBIST, (ii) are not generally known
         and are not disclosed in any published BIOCHEMIE Patents, and (iii) are
         necessary or useful in connection with the research, development,
         manufacture, marketing, promotion, use, sale, import or export of
         Licensed Products, including, without limitation, all data and
         information regarding the safety and efficacy of Licensed Products.

1.9      "BIOCHEMIE Patents" shall mean any and all patents, patent
         applications, utility models and supplementary protection certificates
         (which for the purposes of this Agreement shall be deemed to include
         certificates of invention and applications for certificates of
         invention) that during the term of this Agreement are owned by
         BIOCHEMIE or to which BIOCHEMIE through license or otherwise has or
         acquires sublicenseable rights, in each case that are capable of being
         licensed or sublicensed to CUBIST, and that: (i) claim the structure or
         composition of any Licensed Products or claim any method of use of any
         Licensed Products; (ii) claim any invention necessary or useful in
         connection with the research, development, manufacture, marketing,
         promotion, use, sale, import or export of Licensed Products, including,
         without limitation, all data and information regarding the safety and
         efficacy of Licensed Products; (iii) claim BIOCHEMIE Improvements; (iv)
         are divisions, continuations, continuations-in-part, reissues,
         renewals, extensions, supplementary protection certificates, utility,
         models and the like of any patents and patent applications claiming

<Page>

                                       -3-

         any of the items referred to in the foregoing clauses (i)-(iii); or (v)
         are foreign equivalents or counterparts of any patents or patent
         applications filed in any country and claiming any of the items
         referred to in the foregoing clauses (i)-(iii) or are foreign
         equivalents or counterparts of any of the items referred to in the
         foregoing clause (iv). Notwithstanding the foregoing, the term
         "BIOCHEMIE Patents" shall not include any Joint Patents. Without
         limiting the generality of any of the foregoing, SCHEDULE 1 sets forth
         a list of all BIOCHEMIE Patents as of the Effective Date.

1.10     "BIOCHEMIE Retained Manufacturing Rights" shall have the meaning
         set forth in Section 3.2 hereof.

1.11     "BIOCHEMIE Retained Research Rights" shall have the meaning set
         forth in Section 3.2 hereof.

1.12     "BIOCHEMIE Retained Rights" shall mean both the BIOCHEMIE Retained
         Manufacturing Rights and the BIOCHEMIE Retained Research Rights.

1.13     "BIOCHEMIE Similar Compound" shall mean (i) any cephalosporin
         compound that is listed on SCHEDULE 2, (ii) any cephalosporin compound
         that meets the criteria set forth on SCHEDULE 3 and that is either
         owned or licensed by BIOCHEMIE or (iii) any pharmaceutical composition
         containing any of the items referred to in the foregoing clauses (i)
         and (ii).

1.14     "BIOCHEMIE Trademark" shall mean any registered or unregistered
         trademark or service mark owned or licensed by BIOCHEMIE for use or
         proposed use in conjunction with Licensed Products, including, without
         limitation, any trademark or service mark that BIOCHEMIE has applied to
         register, or applies to register, anywhere in the Territory in
         connection with Licensed Products. Without limiting the generality of
         the foregoing, SCHEDULE 4 sets forth a list of all BIOCHEMIE Trademarks
         as of the Effective Date.

1.15     "Calendar Quarter" shall mean a period of three (3) consecutive
         calendar months ending on March 31, June 30, September 30 or December
         31.

1.16     "Calendar Year" shall mean a period of twelve (12) consecutive
         calendar months commencing on January 1 and ending on December 31.

1.17     "Code" shall have the meaning set forth in Section 9.5(d).

1.18     "Combination Product" shall mean (i) any product or pharmaceutical
         composition

<Page>

                                       -4-

         consisting of, among other things, at least two distinct active
         pharmaceutical ingredients, one of which shall be a Licensed Product or
         (ii) two or more products or pharmaceutical compositions that are
         marketed and sold together in the same package, where at least one of
         such products or pharmaceutical compositions is a Licensed Product and
         at least one of the other products or pharmaceutical compositions are
         not Licensed Products (including, without limitation, (1) a
         pharmaceutical composition containing an active pharmaceutical
         ingredient distinct from the active pharmaceutical ingredient of such
         Licensed Product, (2) a delivery device or (3) a delivery system).

1.19     "Compound" shall mean CAB-175, the structure of which is set forth
         in SCHEDULE 5.

1.20     "CUBIST" shall have the meaning set forth in the preamble.

1.21     "CUBIST Indemnitees" shall have the meaning set forth in Section
         7.2.2.

1.22     "CUBIST Inventions" shall have the meaning set forth in Section
         8.1.

1.23     "Default Major Market Countries" shall have the meaning set forth
         in Section 9.4(a).

1.24     "Directly Competitive Product" shall mean [*] in any formulation
         [*] and [*].

1.25     "Dispute Notice" shall have the meaning set forth in Section 10.1.

1.26     "Effective Date" shall have the meaning set forth in the preamble.

1.27     "FDA" shall mean the United States Food and Drug Administration.

1.28     [*] shall mean, with respect to any country within the Territory,
         [*] that can be sold or otherwise commercialized in such country by [*]
         that does not [*] in such country, and where the sale or other
         commercialization of [*] in such country by [*] does not [*],
         including, without limitation, the [*].

1.29     "ICC" shall have the meaning set forth in Section 10.2(a).

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -5-

1.30     "ICC Rules" shall have the meaning set forth in Section 10.2(a).

1.31     "Intravenous Licensed Product" shall mean any Licensed Product
         formulated for intravenous delivery.

1.32     "Japan License" shall have the meaning set forth in Section 3.3.

1.33     "Joint Development Committee" shall mean the committee established
         pursuant to the Manufacturing and Supply Agreement.

1.34     "Joint Inventions" shall have the meaning set forth in Section
         8.1.

1.35     "Joint Patents" shall mean any and all patents, patent
         applications, utility models and supplementary protection certificates
         (which for the purposes of this Agreement shall be deemed to include
         certificates of invention and applications for certificates of
         invention) that: (i) claim Joint Inventions; (ii) are divisions,
         continuations, continuations-in-part, reissues, renewals, extensions,
         supplementary protection certificates, utility, models and the like of
         any patents and patent applications claiming Joint Information and
         Inventions; or (iii) are foreign equivalents or counterparts of any
         patents or patent applications filed in any country and claiming Joint
         Inventions or are foreign equivalents or counterparts of any of the
         items referred to in the foregoing clause (ii).

1.36     "Licensed Product(s)" shall mean any one or more of the following:
         (i) Compound, (ii) any BIOCHEMIE Similar Compound, (iii) any [*] or
         (iv) any pharmaceutical composition containing any of the items
         referred to in the foregoing clauses (i)-(iii). Each distinct
         formulation (including, but not limited to, any formulations in the
         form of solution for injection, oral suspension and oral solid dosage
         form) of any of the items referred to in the foregoing clauses (i)-(iv)
         shall be [*]. Without limiting the generality of the foregoing, an [*].
         CUBIST's rights to develop and commercialize BIOCHEMIE Similar
         Compounds shall be subject to the limitations set forth in Section
         3.5(a) hereof and CUBIST's rights to commercialize Oral Licensed
         Products shall be subject to the limitations set forth in Section
         3.5(c) hereof.

1.37     "Losses" shall have the meaning set forth in Section 7.2.1.

1.38     "Major Market Countries" shall mean [*].

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -6-

1.39     "Manufacturing and Supply Agreement" shall mean a Manufacturing
         and Supply Agreement to be negotiated and executed by the Parties after
         the Effective Date, pursuant to which, among other things, BIOCHEMIE
         shall agree to manufacture and supply to CUBIST, and CUBIST shall agree
         to purchase from BIOCHEMIE, Licensed Products, all upon such terms and
         conditions as shall be mutually satisfactory to CUBIST and BIOCHEMIE
         and set forth in such Manufacturing and Supply Agreement.

1.40     "NDA" shall mean a New Drug Application filed in the United
         States.

1.41     "Net Sales" shall mean the aggregate gross sales [*] after
         deducting, if not previously deducted, from the amount received:

                  (a)      [*] and as required to do business in the Territory;

                  (b)      [*] and as required to do business in the Territory;

                  (c)      [*]; and

                  (d)      [*].

         For purposes of this Agreement, independent third party distributors of
         CUBIST shall not be deemed to be sublicensees.

         In the event that a Licensed Product is sold as a component of a
         Combination Product, then Net Sales shall be determined by multiplying
         the Net Sales of the Combination Product by the fraction A/(A+B) where
         A EQUALS the average selling price of such Licensed Product sold
         separately in finished form and B EQUALS the aggregate average selling
         price of the relevant other product sold separately in finished form,
         IN EACH CASE in the relevant country in which sales were made. In the
         event that no separate sale of either Licensed Product or the relevant
         other product is made during the applicable royalty reporting period
         and in the relevant country in which the sale of the Combination
         Product was made, then Net Sales shall be determined by multiplying the
         Net Sales of the Combination Product by a fraction (C/(C+D)), where C
         EQUALS CUBIST's standard fully-absorbed cost of Licensed Product and D
         EQUALS the standard fully-absorbed cost of the relevant other product,
         IN EACH CASE determined in accordance with United States generally
         accepted accounting principles for the relevant country in which sales
         were made. If the relevant other product is sold separately in finished
         form and Licensed Product is not, then Net Sales shall be determined by
         multiplying the Net Sales of the Combination Product by the fraction (E
         - B)/E, where E EQUALS the average selling price of the Combination
         Product for the country in which sales were made.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -7-

1.42     "Oral Licensed Product(s)" shall mean any Licensed Product that is
         formulated to be orally bioavailable (including, without limitation, in
         oral suspension form or oral solid dosage form) or that is administered
         to the intended patient population orally.

1.43     "Party" shall have the meaning set forth in the preamble.

1.44     "Person" shall mean any individual, entity, association,
         corporation, partnership, limited liability company, government (or
         agency or subdivision thereof), trust, joint venture, or
         proprietorship.

1.45     "Proprietary Information" shall mean all inventions, discoveries,
         improvements, processes, formulas, materials, know-how and trade
         secrets, and all other scientific, clinical, regulatory, marketing,
         financial and commercial information or data, whether communicated in
         writing or orally or by sensory detection, which is provided by, or on
         behalf of, one Party to the other Party in connection with this
         Agreement or the Manufacturing and Supply Agreement.

1.46     "Section 3.3 CUBIST License" shall have the meaning set forth in
         Section 3.3.

1.47     [*].

1.48     "Territory" shall mean all countries of the world; PROVIDED,
         HOWEVER, that in the event that BIOCHEMIE terminates the Japan License
         pursuant to, and in accordance with, the provisions of Section 3.3,
         then the term "Territory" shall not include Japan.

1.49     "TM Infringement" shall have the meaning set forth in Section 8.9.

1.50     "Valid Claim" shall mean (i) an unexpired claim of an issued
         patent within BIOCHEMIE Patents which has not been found to be invalid
         or unenforceable by a court or other authority in the subject country,
         from which decision no appeal is taken or can be taken; or (ii) a claim
         of a pending patent application within the BIOCHEMIE Patents, which
         patent application claims a first priority no more than ten (10) years
         prior to the date upon which pendency is determined.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -8-

                                   ARTICLE II

         TRANSFER OF KNOW-HOW AND INFORMATION; TECHNICAL ASSISTANCE

2.1      TRANSFER OF KNOW-HOW AND INFORMATION.

         (a)  [*] days of the Effective Date, BIOCHEMIE shall provide CUBIST
              with a written report setting forth a summary and status of all
              BIOCHEMIE Patents and all BIOCHEMIE Know-How as of such date.
              Thereafter, on [*] of each calendar year during the term of this
              Agreement, BIOCHEMIE shall provide CUBIST with a written report
              setting forth a summary and status of (i) all additional BIOCHEMIE
              Know-How that BIOCHEMIE may develop or acquire or that BIOCHEMIE
              has not previously disclosed to CUBIST pursuant to this Section
              2.1(a) and (ii) all BIOCHEMIE Patents that have not been
              previously disclosed to CUBIST pursuant to this Section 2.1(a).
              Promptly after BIOCHEMIE discloses to CUBIST any BIOCHEMIE Patents
              pursuant to this Section 2.1(a) that are not listed on SCHEDULE 1
              to this Agreement, CUBIST and BIOCHEMIE agree to execute and
              deliver to each other a written instrument listing or otherwise
              identifying such BIOCHEMIE Patents and [*] for all purposes of
              this Agreement. From time to time during the term of this
              Agreement (but in no event less frequently than on [*] of each
              calendar year), BIOCHEMIE shall provide CUBIST with a written
              report detailing the activities undertaken by BIOCHEMIE, and the
              results obtained from such activities, in connection with the
              exercise by BIOCHEMIE of the [*]. At any time during the term of
              this Agreement, upon request by CUBIST, BIOCHEMIE shall deliver to
              CUBIST or its designee copies of all [*] specified by CUBIST in
              such request, and copies of all [*] specified in such request.
              From time to time during the term of this Agreement, BIOCHEMIE
              shall also take such actions, and deliver to CUBIST such [*] in
              such request. Notwithstanding anything expressed or implied in
              this Section 2.1(a) to the contrary, [*] under this Section 2.1(a)
              to [*] any [*] to [*] only if and to the extent that such [*].

         (b)  BIOCHEMIE will, as soon as reasonably practicable after the
              Effective Date but in no event later than [*] days after the
              Effective Date, provide CUBIST copies of all regulatory filings,
              and the results of all clinical and non-clinical

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -9-

              testing of Licensed Products performed by or on behalf of
              BIOCHEMIE. On an ongoing basis during the term of this Agreement,
              BIOCHEMIE will provide to CUBIST (i) all information in
              BIOCHEMIE's possession regarding pre-clinical testing and clinical
              testing performed or to be performed by or on behalf of BIOCHEMIE
              with respect to the Licensed Products (including, without
              limitation, information concerning the design and plans with
              respect to such pre-clinical testing or clinical testing) as such
              information becomes available, (ii) the results of all clinical
              and non-clinical testing performed by or on behalf of BIOCHEMIE
              with respect to the Licensed Products as such information becomes
              available, (iii) all information in BIOCHEMIE's possession
              regarding Licensed Products necessary or useful for making
              regulatory filings in the Territory with respect to Licensed
              Products as such information becomes available, and (iv) copies of
              all regulatory filings made by or on behalf of BIOCHEMIE with
              respect to Licensed Products promptly after such regulatory
              filings are made. CUBIST shall have a right of access, a right of
              reference and the right to use and incorporate all information
              provided to it pursuant to this subparagraph (b) in its
              applications for regulatory approvals of Licensed Products within
              the Territory and for all other purposes related to the research,
              development, manufacture, use and commercialization of Licensed
              Products.

         (c)  Notwithstanding anything expressed or implied in the foregoing
              provisions of this Section 2.1 to the contrary, nothing in this
              Section 2.1 or elsewhere in this Article II are intended to
              diminish the scope of the exclusive rights licensed by BIOCHEMIE
              to CUBIST pursuant to Article III below or to suggest that, from
              and after the Effective Date, BIOCHEMIE retains any rights to
              research, develop, seek regulatory approval for, manufacture, use
              or commercialize any Licensed Product, other than the BIOCHEMIE
              Retained Rights.

2.2      BIOCHEMIE ASSISTANCE. During the term of this Agreement, BIOCHEMIE
         shall provide CUBIST with reasonable access to consult with pertinent
         BIOCHEMIE employees (including, but not limited to, [*] that have had
         prior experience working with any Licensed Products or any BIOCHEMIE
         Similar Compound. Except for participation in the Joint Development
         Committee, such consultations shall occur at the request of CUBIST,
         [*]. [*] in connection [*]. The subject matter and scope of such
         consultations shall be defined jointly by CUBIST and BIOCHEMIE and
         shall in any event allow CUBIST to take advantage of such pertinent
         BIOCHEMIE employees' expertise and resources for purposes of assisting
         CUBIST in the research, development, manufacture, use, marketing,
         promotion, sale and other commercialization of Licensed Products.

2.3      HEALTH HAZARDS. BIOCHEMIE will notify CUBIST immediately of any
         material health hazards with respect to Licensed Products that may
         impact employees involved in the research, development, manufacture,
         production or supply of Licensed Products.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -10-

2.4      ENGLISH LANGUAGE. All disclosures or information delivered or made
         available by either Party or its employees and agents to the other
         Party and its employees or agents pursuant to this Article II or any of
         the other provisions of this Agreement or the Manufacturing and Supply
         Agreement shall be made in English.

                                   ARTICLE III
         LICENSE; RETAINED RIGHTS; DILIGENCE; RIGHT OF FIRST NEGOTIATION

3.1      LICENSE GRANT. Subject to the terms and conditions of this
         Agreement (including, without limitation, the rights retained by
         BIOCHEMIE pursuant to Sections 3.2 and 3.3 below and the limitations
         set forth in Section 3.5 below on certain of the rights granted to
         CUBIST in this Section 3.1), BIOCHEMIE hereby grants to CUBIST the
         exclusive right and license (even as to BIOCHEMIE), including the right
         to sublicense, under the BIOCHEMIE Patents, the BIOCHEMIE Know-How and
         the BIOCHEMIE Joint Patent Rights to research, develop, make, have
         made, use, promote, market, sell, offer to sell, import or export
         Licensed Products in the Territory for any and all purposes and uses.
         Notwithstanding the grant by BIOCHEMIE of the foregoing license,
         BIOCHEMIE retains the BIOCHEMIE Retained Rights. CUBIST may grant
         sublicenses of the rights licensed to CUBIST pursuant to this Section
         3.1. It is understood that this Section 3.1 does not provide for the
         license to CUBIST of any rights that a third party may own in or to a
         BIOCHEMIE Similar Compound and that have not been licensed by such
         third party to BIOCHEMIE; PROVIDED, HOWEVER, that such third party has
         not acquired such rights from BIOCHEMIE in violation of the rights
         granted by BIOCHEMIE to CUBIST pursuant to this Section 3.1.

3.2      CERTAIN RESEARCH AND MANUFACTURING RIGHTS RETAINED BY BIOCHEMIE.
         Notwithstanding the license granted pursuant to Section 3.1 above,
         BIOCHEMIE shall retain those rights under the BIOCHEMIE Patents, the
         BIOCHEMIE Know-How and the BIOCHEMIE Joint Patent Rights as may be
         necessary to perform BIOCHEMIE's obligations under the Manufacturing
         and Supply Agreement, including, without limitation, (i) the right to
         engage in technical development relative to chemical, analytical and
         method validation in order to enable the manufacture of Licensed
         Products pursuant to the Manufacturing and Supply Agreement in
         conformity with good manufacturing practices and (ii) the right to
         manufacture Licensed Product pursuant to, and in accordance with, the
         Manufacturing and Supply Agreement (collectively, the "BIOCHEMIE
         RETAINED MANUFACTURING RIGHTS"). In addition, BIOCHEMIE shall retain
         those rights under the BIOCHEMIE Patents, the BIOCHEMIE Know-How and
         the BIOCHEMIE Joint Patent Rights as may be necessary to allow
         BIOCHEMIE to engage only in [*] (the "BIOCHEMIE RETAINED RESEARCH
         RIGHTS"). In no event shall the BIOCHEMIE Retained Research Rights
         include the right of BIOCHEMIE to engage in [*]. BIOCHEMIE shall
         exercise the BIOCHEMIE Retained Manufacturing Rights pursuant to, and
         in accordance with, the Manufacturing and Supply Agreement. The right
         of BIOCHEMIE to exercise the BIOCHEMIE Retained Research Rights shall
         be co-

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -11-

         exclusive with the right of CUBIST, pursuant to Section 3.1 above, to
         engage in research and preclinical development of Licensed Products.
         BIOCHEMIE may not sublicense or assign any of the BIOCHEMIE Retained
         Research Rights or, except to the extent otherwise provided in the
         Manufacturing and Supply Agreement, any of the BIOCHEMIE Retained
         Manufacturing Rights.

3.3      RETAINED RIGHTS TO JAPAN. [*] to terminate the license granted to
         CUBIST pursuant to Section 3.1 with respect to Japan only (such license
         to be referred to as the "JAPAN LICENSE"), if and only if, on or prior
         to [*], [*] that [*]. From and after the date [*] (provided such date
         is no later than [*]. In the event that [*] pursuant to, and in
         accordance with, the provisions of this Section 3.3, [*], by giving
         written notice to [*], a [*] during the period commencing on the
         Effective Date and ending on the effective date of [*] and that are
         necessary and useful to the [*] (the "SECTION 3.3 CUBIST LICENSE").
         Upon CUBIST's receipt of such written notice, [*] for a period not to
         exceed [*] days to see if the [*] for the [*]. In the event that [*],
         the Parties shall, within [*] days after [*] during the period
         commencing on [*] (including, without limitation, [*] and that is [*].
         The [*] shall occur [*] for the [*]. Following the [*], the Parties
         shall, from time to time during the term of this Agreement, [*] within
         the Parties' [*] that was [*] and that is [*]. Any such [*] for such
         [*]. At any time during the term of this Agreement, the [*] within the
         Parties' respective [*] and that is [*]. Any such

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -12-

         [*] by the Parties shall be [*].

3.4      CUBIST'S RIGHT TO ABANDON LICENSED PRODUCTS. CUBIST shall have the
         right to abandon research, development or commercialization of any
         Licensed Product because of [*]. [*]. CUBIST shall exercise its rights
         under this Section 3.4 to abandon research, development or
         commercialization of any Licensed Product by giving written notice of
         such abandonment at least [*] days prior to the effective date of such
         abandonment specified in such written notice. In the event that CUBIST
         exercises its right under this Section 3.4 to abandon research,
         development or commercialization of any Licensed Product, then the
         license granted to CUBIST pursuant to Section 3.1 shall terminate
         automatically with respect to such abandoned Licensed Product only.

3.5      LIMITATION ON CUBIST'S RIGHTS WITH RESPECT TO CERTAIN LICENSED
         PRODUCTS.

         (a)  Notwithstanding any provision in this Agreement to the
              contrary (including, without limitation, the provisions of Section
              3.1 above), CUBIST shall not have the right to develop or
              commercialize any BIOCHEMIE Similar Compound unless otherwise
              provided in Section 3.5(b) below. The foregoing limitation on
              CUBIST's right to develop and commercialize BIOCHEMIE Similar
              Compounds shall not imply or be construed as if BIOCHEMIE, other
              than in the case of the BIOCHEMIE Retained Rights, were retaining
              any right to develop or commercialize any BIOCHEMIE Similar
              Compounds. BIOCHEMIE hereby acknowledges and agrees that it has
              granted to CUBIST an exclusive right and license to all BIOCHEMIE
              Similar Compounds and all other Licensed Products pursuant to the
              provisions of Section 3.1 above and that, although such exclusive
              right and license granted to CUBIST is, in the case of BIOCHEMIE
              Similar Compounds, subject to the limitation set forth in the
              first sentence of this Section 3.5(a), BIOCHEMIE nevertheless,
              except for the BIOCHEMIE Retained Rights, does not retain any of
              the rights granted to CUBIST pursuant to Section 3.1 above,
              including, without limitation, any of the rights granted to CUBIST
              with respect to BIOCHEMIE Similar Compounds.

         (b)  In the event that CUBIST abandons a Licensed Product pursuant
              to, and in accordance with, the provisions of Section 3.4 above
              (in each case, an "ABANDONED PRODUCT"), then CUBIST shall be
              entitled to replace such Abandoned Product with a BIOCHEMIE
              Similar Compound

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                       -13-

              [*]. CUBIST shall exercise its right to replace an Abandoned
              Product pursuant to this Section 3.5(b) by giving written notice
              to BIOCHEMIE no later than [*] days after the abandonment of such
              Abandoned Product, stating that CUBIST is exercising such right.
              Within [*] days after receipt of such written notice given by
              CUBIST, BIOCHEMIE shall [*] the [*]. Any such [*] shall be deemed
              to [*] made by [*] that the [*]. At the time of such [*] all of
              the [*] so [*]. Effective immediately upon such [*] as the [*],
              such BIOCHEMIE Similar Compound shall replace such Abandoned
              Product, the limitations set forth in the first sentence of
              Section 3.5(a) on CUBIST's right to develop and commercialize such
              BIOCHEMIE Similar Compound shall terminate and CUBIST shall be
              entitled to exercise all of the rights granted to it pursuant to
              Section 3.1 above with respect to such BIOCHEMIE Similar Compound.
              The Parties hereby acknowledge that upon the abandonment by CUBIST
              of a BIOCHEMIE Similar Compound selected pursuant to this Section
              3.5(b), BIOCHEMIE may, subject to, and in accordance with, the
              terms and conditions of Section 9.4(c), terminate this Agreement.

         (c)  Notwithstanding any provision in this Agreement to the
              contrary (including, without limitation, the provisions of Section
              3.1 above), [*] unless and until the Parties, in accordance with
              the provisions of Section 6.2 hereof, shall have negotiated in
              good faith the [*]. The foregoing [*] to [*] shall not [*] were
              [*]. [*] that it has [*] and all other [*] and that, although such
              [*], subject to the [*], [*] nevertheless, except for the [*],
              does not [*], including, without limitation, [*] with [*]. In the
              event that [*], then the Parties shall [*] in

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -14-

              connection with such [*] and shall [*] that evidences such [*].

3.6      CUBIST DILIGENCE. Subject to, and in accordance with, the terms and
         conditions of this Agreement and all requirements of applicable laws,
         rules and regulations, CUBIST shall use commercially reasonable efforts
         to research, develop, promote, market, sell, offer to sell and
         otherwise commercialize one Licensed Product in the Major Market
         Countries. The sole remedy of BIOCHEMIE for any breach by CUBIST of its
         obligations under this Section 3.6 is to exercise BIOCHEMIE's special
         termination rights pursuant to Section 9.4 hereof. Any abandonment by
         CUBIST of any Licensed Product pursuant to, and in accordance with, the
         provisions of Section 3.4 hereof shall not be deemed to constitute a
         breach of the provisions of this Section 3.6.

3.7      [*]. Subject to the [*], in the event that [*] to [*] to [*] to [*]
         a [*], [*] shall so [*] with [*] with respect to [*]. If, within [*]
         days after [*] that it [*] such [*], then the [*] of [*] days to see if
         the [*] pursuant to which [*] such [*]. If [*] cannot [*] days, then
         [*] into [*] with [*], and [*] with [*], for the [*] to [*] to [*].
         During the [*] day [*] are [*], such [*] and [*] with [*] regarding the
         [*] to [*] to [*]. Notwithstanding anything expressed or implied in the
         foregoing provisions of this Section 3.7, [*] under this Section 3.7 at
         any time when (i) [*], (ii) the [*] determine that [*] or (iii) [*].
         The Parties acknowledge and agree that, [*], (A) BIOCHEMIE may [*] and
         [*] regarding the [*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -15-

         or to [*] without having [*], and (B) BIOCHEMIE may [*] to [*] to [*]
         if and to the extent that such [*].

3.8      TRADEMARKS. BIOCHEMIE hereby grants CUBIST an exclusive,
         royalty-free license under its entire right, title and interest in and
         to the BIOCHEMIE Trademarks, if any, to use and display the BIOCHEMIE
         Trademarks in connection with the commercialization of Licensed
         Products within the Territory. CUBIST shall not use BIOCHEMIE's trade
         names and/or marks in a way which would be confusing or otherwise
         adversely affect their value. CUBIST shall not be obligated to use
         BIOCHEMIE Trademarks, and shall be free to select, create and use its
         own trade names and marks for its use, in connection with the Licensed
         Products in the Territory.

3.9      USE OF NAME. Neither Party shall use the other Party's name without
         the prior written consent of such other Party, which consent may be
         given or withheld at such other Party's sole discretion.

                                   ARTICLE IV
                                 CONFIDENTIALITY

4.1      NONDISCLOSURE OBLIGATION. All Proprietary Information disclosed by
         or on behalf of one Party to the other Party under this Agreement or
         the Manufacturing and Supply Agreement shall be maintained in
         confidence by the receiving Party and shall not be disclosed to a
         non-Party or used for any purpose whatsoever without the prior written
         consent of the other Party, except to the extent that such Proprietary
         Information:

         (a)  is known by recipient at the time of its receipt, and not
              through a prior disclosure by or on behalf of the disclosing
              Party, as documented by contemporaneous business records;

         (b)  is properly in the public domain through no fault of the
              recipient;

         (c)  is subsequently disclosed to a receiving Party by a third
              party who may lawfully do so and is not directly or indirectly
              under an obligation of confidentiality to the disclosing Party, as
              documented by written business records in existence prior to the
              receipt of such information from the disclosing Party;

         (d)  is developed by the recipient independently of, and without
              reference to or use of, Proprietary Information received from the
              disclosing Party;

         (e)  is required to be disclosed to governmental or other
              regulatory agencies in order to obtain patents, to obtain approval
              to conduct clinical trials or to market Licensed Products, or to
              comply with applicable NASDAQ or Securities and Exchange
              Commission regulations; PROVIDED HOWEVER, that such disclosure may
              be only to the extent reasonably necessary to obtain patents or
              approval, or to

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -16-

              comply with regulations as appropriate and that confidential
              treatment will be sought to the extent reasonably practicable;

         (f)  is disclosed to actual or potential permitted sublicensees or
              permitted assignees and/or other third parties (1) for the purpose
              of conducting activities under this Agreement and the
              Manufacturing and Supply Agreement (or for such actual or
              potential permitted sublicensees or permitted assignees and/or
              other third parties to determine their interest in performing such
              activities) in accordance with this Agreement and the
              Manufacturing and Supply Agreement or (2) for the purpose of
              allowing the Party making such disclosure to effectively exploit
              its rights under this Agreement and the Manufacturing and Supply
              Agreement and obtain all of the benefits under this Agreement and
              the Manufacturing and Supply Agreement to which such Party is
              entitled as contemplated by this Agreement and the Manufacturing
              and Supply Agreement, PROVIDED, HOWEVER, that such actual or
              potential permitted sublicencees or permitted assignees and/or
              other third parties have agreed to be bound by confidentiality
              obligations substantially equivalent to the terms herein for no
              less than five years from the date of disclosure, and PROVIDED,
              FURTHER, that, notwithstanding the provisions set forth above in
              this subsection (f), CUBIST shall not disclose to third party
              manufacturers any Proprietary Information of BIOCHEMIE with
              respect to the manufacture of Licensed Products except to the
              extent that such disclosure is permitted pursuant to the
              provisions of the Manufacturing and Supply Agreement;

         (g)  is disclosed to employees, officers, directors, consultants,
              agents, investors or potential investors of , or lenders or
              potential lenders to, the Party making such disclosure, PROVIDED,
              HOWEVER, that such employees, officers, directors, consultants,
              agents, investors, potential investors, lenders and potential
              lenders have agreed to be bound by confidentiality obligations
              substantially equivalent to the terms herein for no less than five
              years from the date of disclosure, and PROVIDED, FURTHER, that,
              notwithstanding the provisions set forth above in this subsection
              (g), neither Party shall disclose Proprietary Information of the
              other Party to potential investors or potential lenders except to
              the extent that such disclosure is made in the context of such
              potential investors' or potential lenders' due diligence
              investigation of the Party making such disclosure;

         (h)  is used by the receiving Party for the purpose of conducting
              activities under this Agreement and the Manufacturing and Supply
              Agreement in accordance with their respective terms or is used by
              the receiving Party for the purpose of allowing the receiving
              Party to effectively exploit its rights under this Agreement and
              the Manufacturing and Supply Agreement and obtain all of the
              benefits under this Agreement and the Manufacturing and Supply
              Agreement to which such receiving Party is entitled as
              contemplated by this Agreement and the Manufacturing and Supply
              Agreement; or

         (i)  is required to be disclosed by law or court order, PROVIDED
              that notice is promptly delivered to the other party in order to
              provide an opportunity to

<Page>

                                      -17-

              challenge or limit the disclosure obligations, and PROVIDED
              FURTHER that such disclosure may be only to the extent reasonably
              necessary to comply with the applicable law or court order.

4.2      NO DISCLOSURE OF TERMS. Either Party may disclose the existence of
         this Agreement and the Manufacturing and Supply Agreement, but, except
         to the extent otherwise provided below in this Section 4.2, neither
         Party shall disclose the terms of this Agreement or the Manufacturing
         and Supply Agreement without the prior written consent of the other
         Party. Notwithstanding the foregoing, either Party may disclose the
         terms of this Agreement or the Manufacturing and Supply Agreement
         pursuant to the provisions of subparagraphs (b), (e), (f), (g) or (i)
         of Section 4.1 to the same extent as if the terms of this Agreement or
         the Manufacturing and Supply Agreement, as the case may be, were
         Proprietary Information of the non-disclosing Party.

4.3      NO PUBLICATION. BIOCHEMIE shall not publish or present any
         BIOCHEMIE Know-How or any of the inventions claimed under any BIOCHEMIE
         Patents without the prior written consent of CUBIST, which consent
         shall not be unreasonably withheld. Nothing in this Section 4.3 shall
         limit BIOCHEMIE's ability to apply for any patent protection.

4.4      PRESS RELEASES, ETC. Notwithstanding anything set forth in Section
         4.1, 4.2 or 4.3 above to the contrary, the Parties agree that any
         publication, news release or other public announcement by either Party
         relating to this Agreement or the Manufacturing and Supply Agreement or
         to the Parties performance hereunder or thereunder, shall first be
         reviewed and approved by the other Party, which approval shall not be
         unreasonably withheld or delayed. The foregoing provisions of this
         Section 4.4 shall not apply to the extent that the application thereof
         would prevent either Party from complying with any applicable law,
         PROVIDED that such Party shall have used all reasonable efforts to
         comply with the provisions of this Section 4.4 without violating such
         Party's legal obligations. The provisions of this Section 4.4 are not
         intended to narrow the scope of any of the obligations of the Parties
         under Section 4.1, Section 4.2 or Section 4.3 above. Each Party expects
         full compliance by the other Party with all of the provisions of
         Section 4.1, Section 4.2 and Section 4.3 hereof in addition to
         compliance with the provisions of this Section 4.4, if and to the
         extent applicable in any case.

                                    ARTICLE V
                         LICENSE AND MILESTONE PAYMENTS

5.1      CONSIDERATION FOR LICENSE. In consideration for the licenses granted to
         CUBIST under Article III, CUBIST shall, subject to the provisions of
         Section 5.5(c) below, make a cash payment to BIOCHEMIE of [*].

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -18-

5.2      UPFRONTS.

         (a)  Subject to the terms and conditions in this Agreement
              (including, without limitation, the provisions of Sections 5.2(b),
              5.2(c), 5.3 and 5.5 below), CUBIST shall make cash payments to
              BIOCHEMIE in the respective amounts set forth below upon the
              occurrence of the events set forth below:

<Table>
<Caption>
                                         EVENT                                     AMOUNT
         <S>                                                                       <C>
         [*]....................................................................   USD $[*]
         (as further defined in Section 5.3 below)

         [*]....................................................................   USD $[*]
         (as further defined in Section 5.3 below)
</Table>

         (b)  CUBIST shall promptly notify BIOCHEMIE in writing upon the
              occurrence of any of the events set forth above in Section 5.2(a)
              above and CUBIST shall have [*] days to make the corresponding
              payment due. All payments under this Section 5.2 shall be in
              United States dollars.

         (c)  CUBIST shall make the payments set forth in Section 5.2(a)
              only once upon the first occurrence of the applicable event. After
              the occurrence of a given event and the payment required to be
              made by CUBIST pursuant to Section 5.2(a) above in connection with
              the occurrence of such event, no further payment shall be due or
              owed by CUBIST in connection with any subsequent occurrence of
              such event, regardless of how many times the same event occurs in
              connection with the same Licensed Product and regardless of how
              many times the same event occurs with respect to different or
              multiple Licensed Products.

5.3      APPLICABLE CRITERIA FOR THE OCCURRENCE OF CERTAIN EVENTS.

         (a)  For purposes of the first event listed on the table in Section
              5.2(a) above [*], such event shall be deemed to have occurred if
              and when all of the criteria set forth on SCHEDULE 6 have been
              satisfied.

         (b)  For purposes of the second event listed on the table in
              Section 5.2(a) above [*], such event shall be deemed to have
              occurred if and when all of the criteria set forth on SCHEDULE 7
              have been satisfied. The Parties will cooperate in good faith to
              [*].

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -19-

5.4      MILESTONES.

         (a)  Subject to the terms and conditions in this Agreement
              (including, without limitation, the provisions of Sections 5.4(b),
              5.4(c), 5.4(d) and 5.5 below), CUBIST shall make cash payments to
              BIOCHEMIE in the respective amounts set forth below upon
              attainment of the milestones set forth below:

<Table>
<Caption>
                                  EVENT                                 WITH JAPAN             WITHOUT JAPAN
                                                                         LICENSE                  LICENSE
  <S>                                                                    <C>                      <C>
  [*]..................................................................  USD $[*]                 USD $[*]

  [*]..................................................................  USD $[*]                 USD $[*]

  [*]..................................................................  USD $[*]                 USD $[*]

  [*]..................................................................  USD $[*]                 USD $[*]

  [*]..................................................................  USD $[*]                 USD $[*]
</Table>

         (b)  In the event that the Japan License is not terminated by
              BIOCHEMIE pursuant to Section 3.3 hereof, then, upon the
              achievement of the milestones set forth in the table included in
              Section 5.4(a) above, the amount of the payment due by CUBIST
              under Section 5.4(a) above shall be the amount set forth opposite
              the description of such milestone in such table under the caption
              "WITH JAPAN LICENSE". In the event that the Japan License is
              terminated by BIOCHEMIE pursuant to Section 3.3 hereof, then, upon
              the achievement of the milestones set forth in the table included
              in Section 5.4(a) above, the amount of the payment due by CUBIST
              under Section 5.4(a) above shall be the amount set forth opposite

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -20-

              the description of such milestone in such table under the caption
              "WITHOUT JAPAN LICENSE".

         (c)  CUBIST shall promptly notify BIOCHEMIE in writing upon the
              achievement of any of the milestones set forth above in Section
              5.4(a) and CUBIST shall have [*] days to make the corresponding
              milestone payment due. All milestone payments shall be in United
              States dollars.

         (d)  CUBIST shall make the payments set forth in Section 5.4(a)
              only once upon the first achievement of the applicable milestone
              by the first Licensed Product to achieve such milestone. After the
              achievement of a given milestone and the payment required to be
              made by CUBIST pursuant to Section 5.4(a) above in connection with
              the achievement of such milestone, no further payment shall be due
              or owed by CUBIST in connection with such milestone, regardless of
              how many times the same milestone is achieved by the same Licensed
              Product and regardless of how many times the same milestone is
              achieved by different or multiple Licensed Products.

5.5      REDUCTION OF MILESTONE PAYMENTS.

         (a)  Notwithstanding any provision in this Article V or elsewhere
              in this Agreement to the contrary, CUBIST shall be entitled to
              deduct from any and all payments required to be made by CUBIST to
              BIOCHEMIE pursuant to Sections 5.2 and 5.4 above (after giving
              effect to all prior reductions thereof pursuant to this Section
              5.5) [*] that CUBIST [*] in order to [*] by CUBIST anywhere in the
              Territory [*]. The procedures set forth below in the remainder of
              this Section 5.5(a) shall apply and be required with respect to a
              [*] only if and to the extent that [*] to any [*] in order to [*].
              Any failure by [*] shall result in [*] under the foregoing
              provisions of this Section 5.5(a) with respect to any [*] in order
              to [*]. [*] shall give [*] of [*] that it is appropriate to [*] in
              order to [*]. Such [*] of the [*] in order [*]. Upon [*] shall
              have a period of up to [*] days to [*] from

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -21-

              [*] in order to [*]. The [*] such [*] shall be [*] thereof set
              forth in such [*]. BIOCHEMIE hereby agrees to [*] to [*] as [*] of
              [*] and in any event [*] of such [*] day period as possible. In
              the event that, at the end of such [*] day period, [*] to [*],
              then [*] to [*] with [*] and shall have the right to [*], PROVIDED
              that the [*] are [*]. [*] that it shall [*] of such [*] and that
              it shall [*] to [*] in connection with the [*] and as to the [*]
              with [*]. [*] take into account any such [*] and, whenever
              reasonable and practical, [*] with such [*] in response to such
              [*].

         (b)  Notwithstanding any provision in this Article V or elsewhere
              in this Agreement to the contrary, (I) in the event that there is
              no [*] with respect to the [*] in at least one Licensed Product
              such that the [*] of such Licensed Product by a [*] would not [*]
              of such [*], then CUBIST shall be entitled to [*] that CUBIST is
              required to make to [*] an [*] to [*], and (II) in the event that
              there is no [*] with respect to the [*] in at least one Licensed
              Product such that the [*] of such Licensed Product by a [*] would
              not constitute [*] of such [*], then CUBIST shall not be required
              to [*].

         (c)  Notwithstanding any provision in this Article V or elsewhere
              in this Agreement to the contrary, in the event that this
              Agreement is executed and delivered after July 31, 2002, then the
              amounts payable by CUBIST pursuant to Sections 5.1 and 5.2 shall
              be reduced by [*], PROVIDED HOWEVER, in no event shall the
              aggregate amount of such

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -22-

              reductions exceed [*]. The [*] pursuant to the provisions of this
              Section 5.5(c) shall be charged all to the payment due by CUBIST
              pursuant to Section 5.1 hereof. The [*] shall be charged to the
              payment due upon the occurrence of the first event described in
              Section 5.2(a) above and the [*] shall be charged to the payment
              due upon the occurrence of the second event described in Section
              5.2(a) above. Thereafter, any [*] shall continue to be charged in
              iterative fashion to the payment due by CUBIST pursuant to Section
              5.1 hereof, the payment due by CUBIST pursuant to Section 5.2(a)
              upon the occurrence of the first event and the payment due by
              CUBIST pursuant to Section 5.2(a) upon the occurrence of the
              second event, [*] or the aggregate amount of such reductions is
              equal to [*]. The provisions of this Section 5.5(c) shall only
              entitle CUBIST to reduce the amount of certain payments that it
              would otherwise owe BIOCHEMIE and such provisions shall in no
              event be construed or interpreted as requiring BIOCHEMIE to make
              payments to CUBIST in the event that the amount of the reductions
              contemplated under this Section 5.5(c) exceed the amount of the
              payments that CUBIST would otherwise owe BIOCHEMIE.

                                   ARTICLE VI
                                    ROYALTIES

6.1      ROYALTIES ON LICENSED PRODUCTS THAT ARE NOT ORAL LICENSED PRODUCTS.
         In consideration of the license granted to CUBIST pursuant to Section
         3.1, CUBIST shall pay to BIOCHEMIE, subject to the terms and conditions
         of this Agreement (including, without limitation, the provisions of
         Sections 6.3, 6.4, 6.5 and 6.10), a royalty on the aggregate annual Net
         Sales for all Licensed Products [*] and that are sold in the Territory,
         equal to [*] of aggregate annual Net Sales for all of such Licensed
         Products [*].

6.2      [*]. CUBIST and BIOCHEMIE shall, prior to commercial launch of any
         [*], negotiate in good faith a commercially reasonable royalty for each
         [*] that is sold in the Territory. Any such royalty shall be paid by
         CUBIST in consideration of the license granted to CUBIST pursuant to
         Section 3.1 in respect to [*]. Payment of any such royalty shall be
         subject to the terms and conditions of this Agreement (including,
         without limitation, the provisions of Sections 6.3, 6.4, 6.5 and 6.10
         hereof.

6.3      TERM OF ROYALTIES. BIOCHEMIE's right to receive royalties under
         Section 6.1 and Section 6.2 shall expire on a country-by-country and
         product-by-product basis upon the later of (i) [*] years from the first
         commercial sale of the applicable Licensed Product in the applicable
         country in the Territory or (ii) the expiration of the last to expire
         Valid Claim that, absent the license granted to CUBIST pursuant to
         Section 3.1 hereof, would be

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -23-

         infringed by the sale or commercialization of such Licensed Product in
         such country. In the event that BIOCHEMIE's right to receive royalties
         under Section 6.1 or Section 6.2 expires with respect to any Licensed
         Product in any country within the Territory pursuant to the provisions
         of this Section 6.3, then the [*] for purposes of calculating any
         royalty owed by CUBIST to BIOCHEMIE pursuant to Section 6.1 or Section
         6.2 above. In the event that, in accordance with the provisions of this
         Section 6.3, the right of BIOCHEMIE to receive royalties in connection
         with sales of License Product in any country in the Territory expires,
         CUBIST shall nevertheless remain obligated to pay royalties to
         BIOCHEMIE in connection with all sales of Licensed Product in such
         country that occurred prior to such expiration, and CUBIST shall no
         longer be obligated to pay royalties to BIOCHEMIE in connection with
         any and all sales of Licensed Product in such country that occur on or
         after such expiration.

6.4      REDUCTION OF ROYALTY.

         (a)  Notwithstanding any provision in this Article VI or elsewhere
              in this Agreement to the contrary, (I) in the event that there is
              no [*] in any given country within the Territory with respect to
              the [*] in any Licensed Product such that the [*] of such Licensed
              Product by a [*] in such country would not [*] of such [*], then
              the portion of total royalties that would otherwise be payable by
              CUBIST to BIOCHEMIE pursuant to Section 6.1 or Section 6.2, as
              applicable, (after giving effect to all other reductions of such
              total royalties pursuant to this Section 6.4) as a result of the
              Net Sales of such Licensed Product in such country shall be
              reduced by [*] and (II) in the event that there is no [*] in any
              given country within the Territory with respect to the [*] in any
              Licensed Product such that the [*] of such Licensed Product by a
              [*] in such country would not [*] of such [*], then the portion of
              total royalties that would otherwise be payable by CUBIST to
              BIOCHEMIE pursuant to Section 6.1 or Section 6.2, as applicable,
              (after giving effect to all other reductions of such total
              royalties pursuant to this Section 6.4) as a result of the Net
              Sales of such Licensed Product in such country shall be [*].
              CUBIST agrees to give BIOCHEMIE [*] days notice prior to the [*]
              in any country in the Territory in which CUBIST intends to [*] and
              in which CUBIST is not aware that any [*].

         (b)  Notwithstanding any provision in this Article VI or elsewhere
              in this Agreement to the contrary, in the event that CUBIST [*] in
              order to

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -24-

              [*] by CUBIST in any country within the Territory [*], then the
              portion of total royalties that would otherwise be payable by
              CUBIST to BIOCHEMIE pursuant to Section 6.1 or Section 6.2, as
              applicable, (after giving effect to all other reductions of such
              total royalties pursuant to this Section 6.4) as a result of the
              Net Sales of such Licensed Product in such country shall be
              reduced [*] by the [*] on account of the Net Sales of such
              Licensed Product in such country.

6.5      ROYALTY PAYMENTS AND REPORTS. Royalties shall be calculated by
         converting all applicable Net Sales into U.S. dollars (other than Net
         Sales with respect to sales of Licensed Products as to which CUBIST's
         royalty payment obligation, as provided below in this Section 6.5, is
         in Euros) in accordance with the provisions of Section 6.8 below and
         applying the appropriate royalty percentages set forth in, or
         determined in accordance with, Section 6.1 or Section 6.2, as
         applicable. During the term of this Agreement, royalties shall be paid
         within [*] days after the close of each fiscal year of CUBIST, and
         royalty payments shall be made in the following currencies: (i) in the
         case that a portion of CUBIST's royalty payment obligation is
         attributable to sales of Licensed Products [*], CUBIST shall make
         payment [*]; and (ii) in the case that a portion of CUBIST's royalty
         payment obligation is attributable to sales of License Products [*],
         CUBIST shall make payment [*]. Within [*] days of the end of each
         fiscal year of CUBIST, CUBIST shall furnish to BIOCHEMIE a report
         showing: (i) the calculation of Net Sales [*] for all Licensed Products
         [*] and that were sold in the Territory on a country-by-country basis
         during such fiscal year, (ii) the calculation of Net Sales [*] for each
         [*] that was sold in the Territory on a country-by-country basis during
         such fiscal year, (iii) royalties accrued to BIOCHEMIE pursuant to
         Section 6.1 and pursuant to Section 6.2 during such fiscal year, (iv)
         the amount of any credits or off-sets against royalties (if any), and
         (v) the currency exchange rates used in determining the amount of [*],
         as applicable, payable to BIOCHEMIE. If no royalty payments are due for
         any period hereunder, CUBIST shall so report. All reports delivered
         pursuant to this Section 6.5 and any information that can be derived
         therefrom shall constitute Proprietary Information of CUBIST for
         purposes of Section 4.1 hereof.

6.6      RECORDKEEPING BY CUBIST. CUBIST shall keep, and shall cause each of
         its sublicensees to keep, full and accurate books of account containing
         all particulars that may be necessary for the purpose of calculating
         Net Sales and all royalty payments payable to BIOCHEMIE pursuant to
         Section 6.1 or Section 6.2, as applicable. Such books of account shall
         be kept at CUBIST's principal place of business and, with all necessary
         supporting data shall, for the [*] years next following the end of the
         calendar year to which each shall pertain be open for inspection by
         BIOCHEMIE.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -25-

6.7      AUDITS. Upon the written request of BIOCHEMIE, CUBIST shall permit
         an independent certified public accounting firm of nationally
         recognized standing selected by BIOCHEMIE and reasonably acceptable to
         CUBIST, at BIOCHEMIE's expense, to have reasonable access during normal
         business hours to such of the records of CUBIST or its sublicensees as
         may be reasonably necessary to verify the accuracy of the royalty
         reports hereunder in respect of any calendar quarter ending not more
         than [*] months prior to the date of such request. All such
         verifications shall be conducted not more than once in each Calendar
         Year during the term of this Agreement. If such accounting firm
         concludes that additional payments were owed during such period and
         there is no dispute concerning whether such payments are owed, CUBIST
         shall pay the additional payments within [*] days of the date BIOCHEMIE
         delivers to CUBIST such accounting firm's written report so concluding.
         If such accounting firm concludes that CUBIST made payments to
         BIOCHEMIE in excess of what CUBIST was required to pay BIOCHEMIE
         pursuant to the terms of this Agreement, then BIOCHEMIE shall return
         such excess payments to CUBIST within [*] days of the date of such
         accounting firm's written report concluding that such excess payments
         were made. BIOCHEMIE shall promptly inform CUBIST of the findings of
         any accounting firm engaged by BIOCHEMIE for any of the purposes
         contemplated under this Section 6.7, and shall promptly deliver to
         CUBIST a copy of any written report prepared by such accounting firm.
         The fees and expenses of any such accounting firm shall be borne by
         BIOCHEMIE unless such accounting firm determines that CUBIST underpaid
         royalties due to BIOCHEMIE during any year by more than [*], in which
         case CUBIST shall make payment of all of such fees and expenses.

6.8      EXCHANGE RATE. The rate of exchange to be used in computing Net
         Sales in each country within the Territory shall be made at the average
         rate of exchange for such country's currency published in the Wall
         Street Journal (New York Edition) for each business day of the fiscal
         year to which such Net Sales relate.

6.9      INTEREST ON OVERDUE PAYMENTS. Any amounts not paid by CUBIST or
         BIOCHEMIE when due under this Agreement shall be subject to interest
         from and including the date payment is due through and including the
         date upon which CUBIST or BIOCHEMIE, as the case may be, has made such
         payment at a rate equal to [*] quoted in the Money Rates section of the
         Wall Street Journal (New York Edition) calculated daily on the basis of
         a 365-day year, or similar reputable data source, or, if lower, the
         highest rate permitted under applicable law.

6.10     TAXES. If CUBIST is required by law, rule or regulation to
         withhold taxes from any payments due to BIOCHEMIE from CUBIST
         hereunder, CUBIST will (i) deduct those taxes from the remittable
         amount, (ii) pay the taxes to the proper taxing authority, and (iii)
         send evidence of the obligation together with proof of payment to
         BIOCHEMIE within [*] business days following that payment. Without
         limiting the generality of the foregoing provisions of this Section
         6.10, CUBIST shall be responsible for all taxes imposed on or
         attributable to it under applicable law and BIOCHEMIE shall be
         responsible for all taxes imposed on or attributable to it under
         applicable law.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -26-

                                   ARTICLE VII
                    REPRESENTATIONS, WARRANTIES AND INDEMNITY

7.1      REPRESENTATIONS AND WARRANTIES.

7.1.1    MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party hereby
         represents and warrants to the other Party that:

         (a)  it is a corporation duly organized, validly existing and in
              good standing under the laws of the jurisdiction in which it is
              incorporated, and has full corporate power and authority and the
              legal right to own and operate its property and assets and to
              carry on its business as it is now being conducted and as
              contemplated in this Agreement;

         (b)  it has the corporate power and authority and the legal right
              to enter into this Agreement and perform its obligations
              hereunder; it has taken all necessary corporate action on its part
              required to authorize the execution and delivery of this Agreement
              and the performance of its obligations hereunder; and this
              Agreement has been duly executed and delivered on behalf of such
              Party, and constitutes a legal, valid and binding obligation of
              such Party that is enforceable against it in accordance with its
              terms;

         (c)  it has not entered, and will not enter, into any agreement
              with any third party that is in conflict with the rights granted
              to the other Party under this Agreement, and has not taken and
              will not take any action that would in any way prevent it from
              granting the rights granted to the other Party under this
              Agreement, or that would otherwise materially conflict with or
              adversely affect the rights granted to the other Party under this
              Agreement;

         (d)  its performance and execution of this Agreement will not
              result in a breach of any other contract to which it is a party;
              and

         (e)  in the course of the development of Licensed Products, such
              Party shall not have used and shall not use any employee or
              consultant that has been debarred by the FDA or other regulatory
              authority, or, to the best of such Party's knowledge, is the
              subject of debarment proceedings by the FDA or other regulatory
              authority.

7.1.2    BIOCHEMIE GENERAL REPRESENTATIONS AND WARRANTIES. BIOCHEMIE
         represents and warrants that:

         (a)  BIOCHEMIE has not taken any action to encumber any of its
              right, title and interest in BIOCHEMIE Patents or BIOCHEMIE
              Know-How in the Territory;

         (b)  BIOCHEMIE has sufficient rights in and to the BIOCHEMIE
              Patents and BIOCHEMIE Know-How to grant the rights set forth in
              this Agreement to CUBIST;

<Page>

                                      -27-

         (c)  BIOCHEMIE has not and shall not misappropriate the trade
              secrets or intellectual property rights of any other Person in its
              activities to develop the BIOCHEMIE Patents and the BIOCHEMIE
              Know-How;

         (d)  BIOCHEMIE is unaware of any activities by third parties that
              would constitute infringement of BIOCHEMIE Patents or
              misappropriation of BIOCHEMIE Know-How or of any of the inventions
              claimed under the BIOCHEMIE Patents;

         (e)  the exercise of the licenses granted to CUBIST under the
              BIOCHEMIE Patents and BIOCHEMIE Know-How, including for the
              research, development, use, manufacture, promotion, marketing,
              sale, offer for sale, import and export of Licensed Products in
              the Territory do not infringe any intellectual property rights
              owned or possessed by any third party which such intellectual
              property is published prior to the Effective Date;

         (f)  it is not aware of any claims, judgments or settlements
              against or owed by BIOCHEMIE and has not received notice of any
              pending or threatened claims or litigation relating to the
              BIOCHEMIE Patents or BIOCHEMIE Know-How; and

         (g)  as of the Effective Date, BIOCHEMIE does not own or have any
              rights to develop, manufacture or commercialize any cephalosporin
              compound that meets the criteria set forth on SCHEDULE 3 and is
              not described or listed on SCHEDULE 2.

7.2      INDEMNITY.

7.2.1    CUBIST hereby agrees to defend, hold harmless and indemnify
         BIOCHEMIE and its agents, directors, officers and employees (the
         "BIOCHEMIE INDEMNITEES") from and against any and all suits, claims,
         actions, demands, liabilities, expenses and/or losses, including,
         without limitation, reasonable legal expenses and attorneys' fees
         (collectively "LOSSES") resulting directly or indirectly from:

         (a)  a material breach of any of the provisions of this Agreement
              by CUBIST or any of its agents or employees; or

         (b)  the negligence, recklessness, or willful misconduct by CUBIST
              or any of its agents or employees in the performance of any
              obligations of CUBIST under this Agreement.

7.2.2    BIOCHEMIE hereby agrees to defend, hold harmless and indemnify
         CUBIST and its agents, directors, officers, employees, sublicensees and
         distributors (the "CUBIST INDEMNITEES") from and against any and all
         Losses resulting directly or indirectly from:

         (a)  a material breach of any of the provisions of this Agreement
              by BIOCHEMIE or any of its agents or employees;

<Page>

                                      -28-

         (b)  the negligence, recklessness, or willful misconduct by
              BIOCHEMIE or any of its agents or employees in the performance of
              any obligations of BIOCHEMIE under this Agreement;

         (c)  the infringement of any third party intellectual property
              right which such intellectual property is published prior to the
              Effective Date, [*], and any related patents, foreign equivalents,
              or counterparts, caused by the research, development, manufacture,
              use, promotion, marketing, sale, offer for sale, importation or
              exportation of Licensed Products in the Territory by CUBIST and
              its sublicensees or distributors, other than infringement
              resulting from work performed by CUBIST on Compound or BIOCHEMIE
              Similar Compound as part of the development of Compound or
              BIOCHEMIE Similar Compound provided such infringement does not
              relate to, involve or arise from (i) BIOCHEMIE Patents or
              BIOCHEMIE Know-How, (ii) CUBIST's use thereof, or (iii) the
              exercise by CUBIST of its licensed rights thereto; or

         (d)  the misappropriation of any third party intellectual property
              right by BIOCHEMIE or any of its agents or employees.

7.2.3    If either Party is seeking indemnification under this Section 7.2
         in connection with a third party claim, it shall inform the
         indemnifying Party of such third party claim giving rise to the
         obligation to indemnify as soon as reasonably practicable after
         receiving notice of the claim. Subject to the provisions of Section
         8.6(b) hereof, the indemnifying Party shall have the right to assume
         the defense of, and take control of, any such third party claim for
         which it is obligated to indemnify the indemnified Party under this
         Section 7.2. The indemnified Party shall cooperate with the
         indemnifying Party (and its insurer) as the indemnifying Party may
         reasonably request. The indemnified Party shall have the right to
         participate, at its own expense and with counsel of its choice, in the
         defense of any claim or suit that has been assumed by the indemnifying
         Party. Neither Party shall have any obligation to indemnify the other
         Party in connection with any settlement made without the indemnifying
         Party's written consent, provided that the indemnifying Party does not
         unreasonably withhold or delay any such written consent.

7.2.4    Notwithstanding anything expressed or implied to the contrary in
         this Article VII, the amount of any Losses subject to indemnification
         shall be reduced by the amount of any insurance proceeds received by
         the indemnified Party with respect to such Losses; and there shall be
         no obligation under this Agreement to indemnify such indemnified Party
         for the amount of Losses so reduced.

7.3      LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER
         PARTY FOR LOST PROFITS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL,
         SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OF THE OTHER PARTY IN CONNECTION
         WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT,
         HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -29-

7.4      INSURANCE. BIOCHEMIE and CUBIST shall each procure and maintain
         insurance, including product liability insurance, adequate to cover its
         obligations hereunder and that are consistent with normal business
         practices of prudent companies similarly situated. It is understood
         that such insurance shall not be construed to create a limit of the
         Parties' liability with respect to its indemnification obligations
         under this Article VII. CUBIST and BIOCHEMIE shall provide each other
         with written evidence of such insurance upon request (which evidence
         need not necessarily be insurance certificates). CUBIST and BIOCHEMIE
         shall provide the other with written notice at least ten (10) days
         prior to the cancellation, non-renewal or material change in such
         insurance that materially adversely affects the other Party's rights
         hereunder.

                                  ARTICLE VIII
                        INTELLECTUAL PROPERTY PROVISIONS

8.1      INVENTIONS. The entire right, title and interest in and to all
         discoveries, improvements, processes, formulas, data, inventions,
         enhancements, know-how and trade secrets, patentable or otherwise, that
         arise from activities under this Agreement or the Manufacturing and
         Supply Agreement or that are necessary or useful in connection with the
         research, development, manufacture, marketing, promotion, use, sale,
         import or export of Licensed Products, and that were or are developed
         or invented:

         (a)  solely by employees of CUBIST ("CUBIST INVENTIONS") shall be
              owned solely by CUBIST;

         (b)  solely by employees of BIOCHEMIE ("BIOCHEMIE INVENTIONS")
              shall be owned solely by BIOCHEMIE; and

         (c)  jointly by employees of CUBIST and BIOCHEMIE ("JOINT
              INVENTIONS") shall be owned jointly by CUBIST and BIOCHEMIE.

         Inventorship shall be determined in accordance with U.S. patent laws.

8.2      FILING, PROSECUTION AND MAINTENANCE OF PATENTS. CUBIST shall be
         entitled to file, prosecute and maintain in the Territory all patent
         applications and patents that claim any CUBIST Inventions. BIOCHEMIE
         agrees to file, prosecute and maintain in [*] and, to the extent
         included [*] , upon appropriate consultation with CUBIST, the BIOCHEMIE
         Patents. Except to the extent otherwise provided pursuant to the next
         sentence, BIOCHEMIE may, at its discretion, choose to file, prosecute
         and maintain the BIOCHEMIE Patents in [*] upon appropriate consultation
         with CUBIST. BIOCHEMIE shall also file, prosecute and maintain the
         BIOCHEMIE Patents in any country in the Territory [*]. In the event
         that BIOCHEMIE is unwilling, unable or otherwise fails to file any
         BIOCHEMIE Patents in any country in the Territory [*], then CUBIST
         shall have such right and, upon exercise of such right by CUBIST,
         CUBIST shall be entitled to file, prosecute and maintain such BIOCHEMIE
         Patents in such country, and BIOCHEMIE shall

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -30-

         [*] as may be reasonably necessary to allow [*] in such country in a
         timely manner. [*] shall have the first right to file, prosecute and
         maintain in the Territory, upon appropriate consultation with [*],
         Joint Patents; HOWEVER, in the event that [*] elects not to file any
         patent application in the Territory with respect to any Joint
         Invention, [*] shall have such right and upon exercise by [*] of such
         right, [*] shall have the right to prosecute and maintain in the
         Territory, upon appropriate consultation with [*], the Joint Patents to
         which such Joint Invention relates. Each of BIOCHEMIE and CUBIST shall
         execute such documents and perform such acts as may be reasonably
         necessary to allow [*], in the first instance, and [*], in the second
         instance, to file, prosecute and maintain Joint Patents in any country
         within the Territory in a timely basis. In each case, the filing Party
         shall give the non-filing Party an [*] before filing (but in no event
         less than [*] days), shall [*] with the non-filing Party with respect
         thereto, shall, prior to filing any application, [*] that the
         non-filing Party [*] on a timely basis to such application and shall
         supply the non-filing Party with a copy of the application as filed,
         together with notice of its filing date and serial number and all
         substantive prosecution. Each Party shall keep the other advised of the
         status of the actual and prospective patent filings described above in
         this Section 8.2 and, upon the request of the other, [*] related to the
         filing, prosecution and maintenance of such patent filings. [*] shall
         promptly give notice to [*] of the grant, lapse, revocation, surrender,
         invalidation or abandonment in the Territory of any Joint Patent being
         prosecuted by [*]. [*] shall promptly give notice to [*] of the grant,
         lapse, revocation, surrender, invalidation or abandonment of any [*]or
         [*] being prosecuted by [*]. With respect to all filings hereunder, the
         filing Party shall be responsible for payment of all costs and expenses
         related to such filings.

8.3      OPTION OF THE PARTIES TO PROSECUTE AND MAINTAIN PATENTS. Each Party
         shall give notice to the other Party of any desire to cease prosecution
         and/or maintenance in the Territory of [*] or [*] that such Party is
         then prosecuting or maintaining, and, in such case, shall permit the
         other Party, in its sole discretion, to continue such prosecution or
         maintenance in the Territory at its own expense. If the other Party
         then elects to continue prosecution or maintenance in the Territory,
         each Party shall execute such documents and perform such acts as may be
         reasonably necessary to effect a Power of Attorney of such [*] or [*],
         as the case may be, to the other in a timely manner to allow
         continuation of such prosecution or maintenance in the Territory.

8.4      OPPOSITION, REEXAMINATION AND REISSUE.

         (a)  Each Party shall, within [*] days of learning of such event,
              inform the other of any request for, or filing or declaration of,
              any interference, opposition, reexamination, revocation, nullity
              proceeding or declaration of non-infringement (or the equivalent
              of any of the foregoing) in the Territory relating to the [*] or
              the [*], as the case may be. BIOCHEMIE and CUBIST shall thereafter
              consult and cooperate fully to determine a course of

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -31-

              action with respect to any such proceeding. Each Party shall have
              the right to review and approve any submission to be made in
              connection with such proceeding.

         (b)  [*] shall not initiate any reexamination, interference,
              reissue, revocation, nullity or declaration of non-infringement
              proceeding in the Territory relating to [*] or [*] without the
              prior written consent of [*], which consent shall not be
              unreasonably withheld. [*] shall not initiate any reexamination,
              interference, reissue, revocation, nullity or declaration of
              non-infringement proceeding in the Territory relating to [*] or
              [*] without the prior written consent of [*], which consent shall
              not be unreasonably withheld.

         (c)  In connection with any interference, opposition,
              reexamination, reissue, revocation, nullity or declaration of
              non-infringement proceeding (or the equivalent of any of the
              foregoing) in the Territory relating to [*] or [*], BIOCHEMIE and
              CUBIST will cooperate fully and will provide each other with any
              information or assistance that either may reasonably request. The
              Parties shall keep each other informed of developments in any such
              action or proceeding, including to the extent permissible by law
              and contracts, the status of any settlement negotiations and the
              terms of any offer related thereto.

         (d)  BIOCHEMIE, in the case of BIOCHEMIE Patents, shall bear the
              expense of any interference, opposition, reexamination, reissue,
              revocation, nullity or declaration of non-infringement proceeding
              (or the equivalent of any of the foregoing) relating thereto. The
              expenses of any interference, opposition, reexamination, reissue,
              revocation, nullity or declaration of non-infringement proceeding
              with respect to Joint Patents shall be shared equally by the
              Parties.

         (e)  This Section 8.4 relates only to proceedings before the United
              States Patent and Trademark Office or other applicable patent
              authorities. Any revocation, nullity or declaration of
              non-infringement proceeding before a court, arbitration panel or
              similar body, shall not be governed by this Section 8.4 but shall
              be governed by Sections 8.5 and 8.6 hereof.

8.5      ENFORCEMENT.

         (a)  BIOCHEMIE shall give CUBIST notice of (i) any infringement of
              BIOCHEMIE Patents or Joint Patents, (ii) any misappropriation or
              misuse of BIOCHEMIE Know-How, or (iii) any infringement or
              misappropriation of any CUBIST Inventions (regardless of whether
              or not such Cubist Inventions have been claimed in a patent or
              patent application filed by CUBIST), in each case that may come to
              BIOCHEMIE's attention. CUBIST shall give BIOCHEMIE notice of (A)
              any infringement of BIOCHEMIE Patents or Joint Patents or (B) any
              misappropriation or misuse of BIOCHEMIE Know-How, in each case
              that may come to CUBIST's attention. BIOCHEMIE and CUBIST shall
              thereafter consult

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -32-

              and cooperate fully to determine a course of action, including but
              not limited to the commencement of legal action by either or both
              BIOCHEMIE and CUBIST, to terminate any infringement of [*] or [*]
              or to terminate any [*]. [*], upon notice to [*], shall [*], at
              [*] and [*], and as appropriate, [*], with respect to [*]. In the
              event that [*] elects not to [*], then [*] shall promptly inform
              [*] of [*] election and [*] shall thereafter [*] and, if
              necessary, [*]. Each Party shall [*].

         (b)  For any infringement action concerning [*] or [*] or any
              misappropriation or misuse of [*] or [*], in the event that [*]
              but is unable to do so [*], [*] will [*], and at [*] expense, will
              execute all documents necessary for [*] to initiate litigation to
              prosecute and maintain such action. In the event that [*] elects
              to be represented by its own counsel in connection with any matter
              pertaining to such action, [*] shall pay all of the costs and
              expenses of its own counsel. In connection with any such action,
              BIOCHEMIE and CUBIST will cooperate fully and will provide each
              other with any information or assistance that either may
              reasonably request. The Parties shall keep each other informed of
              developments in any such action or proceeding, including to the
              extent permissible by law and contracts, the status of any
              settlement negotiations and the terms of any offer related
              thereto.

         (c)  Any recovery of damages or an award obtained by either or both
              of BIOCHEMIE and CUBIST in connection with or as a result of any
              action contemplated by this Section 8.5 or Section 8.6 below,
              whether by settlement or otherwise, shall be shared in order as
              follows:

              (i)   the Party or Parties that prosecuted the action shall
                    recoup all of its or their costs and expenses incurred in
                    connection with the action;

              (ii)  the other Party (to the extent that it did not
                    prosecute the action) shall then, from funds remaining,
                    recover its costs and expenses incurred in connection with
                    the action to the extent that such costs and expenses are
                    reasonably incurred to comply with such Party's obligations
                    under Section 8.5 or to the extent that such other Party
                    participates in the prosecution of such action but not as a
                    party thereto; and

              (iii) any amount remaining shall be allocated [*] to CUBIST
                    and [*] to BIOCHEMIE.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -33-

8.6      DEFENSE OF THIRD PARTY INFRINGEMENT CLAIMS.

         (a)  NOTICE. If any Licensed Product becomes the subject of a third
              party claim, or there is the potential for a claim, of patent
              infringement relating to the research, development, use,
              manufacture, promotion, marketing, sale, offer for sale,
              importation or exportation of such Licensed Product in the
              Territory, the Party first having notice of the claim shall
              promptly notify the other Party, and the Parties shall promptly
              meet to consider the claim and the appropriate course of action.

         (b)  DEFENSE. Except as provided herein, the Party against which
              such third party infringement claim is brought shall defend
              against such claim at its sole expense and the other Party shall
              have the right, but not the obligation, to participate in any such
              suit, at its sole option and at its own expense. Such other Party
              shall reasonably cooperate with the Party conducting the defense
              of the claim. Notwithstanding the foregoing provisions of this
              Section 8.6(b), BIOCHEMIE shall have the obligation to assume the
              defense of any infringement claim for which BIOCHEMIE must
              indemnify CUBIST pursuant to Section 7.2.2(c) hereof.

         (c)  SETTLEMENT. Neither Party shall enter into any settlement that
              materially affects the other Party's rights or interests without
              such other Party's written consent, which consent shall not be
              unreasonably withheld or delayed.

8.7      PATENT TERM RESTORATION AND REGULATORY EXCLUSIVITY. The Parties
         shall cooperate with each other in obtaining patent term restoration or
         extension, supplementary protection certificates, regulatory data
         extensions or exclusivity, or their equivalents, in the Territory where
         applicable to [*]. [*] shall have the first right to make any elections
         in the Territory regarding such patent term restoration or extension or
         regulatory extension or exclusivity with respect to [*], as applicable.
         If CUBIST decides not to obtain patent term restoration or extension or
         regulatory extension or exclusivity in the Territory with respect to
         [*], as applicable, BIOCHEMIE shall, at its sole cost and expense, have
         the right to obtain any such patent term restoration or extension or
         regulatory extension or exclusivity in the Territory. In such event,
         the Parties shall cooperate with each other, including providing copies
         of relevant regulatory submissions and correspondence and executing
         requisite documentation.

8.8      PATENT MARKING. CUBIST shall mark all Licensed Products sold with
         appropriate patent numbers or indicia at BIOCHEMIE's request to the
         extent required and/or permitted by law.

8.9      TRADEMARKS. CUBIST shall have the right to determine appropriate
         trademark, trade dress and other related intellectual property usage in
         connection with marketing Licensed Products under this Agreement.
         CUBIST shall have the exclusive right to use any trademarks in
         connection with marketing Licensed Products under this Agreement

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -34-

         in the Territory. Each Party shall notify the other Party promptly upon
         learning of any actual, alleged or threatened infringement of any
         BIOCHEMIE Trademark or CUBIST trademark or of any unfair trade
         practices, trade dress imitation, passing off of counterfeit goods, or
         like offenses, or any such claims brought by a third party against a
         Licensed Product (hereinafter "TM INFRINGEMENT"). Upon learning of such
         TM Infringement, the Parties shall confer as to the best response to
         such TM Infringement. CUBIST shall have the sole right, in its own
         discretion and at its own expense, to bring an action to address such
         TM Infringement, in which case the proceeds thereof shall be allocated
         FIRST to pay CUBIST's costs and expenses in connection with such
         action, SECOND to pay any costs and expenses incurred by BIOCHEMIE in
         connection with such action, and THIRD [*] to CUBIST and [*] to
         BIOCHEMIE.

                                   ARTICLE IX
                              TERM AND TERMINATION

9.1      TERM. This Agreement shall be effective as of the Effective Date
         and, unless terminated pursuant to Section 9.2 or Section 9.3 below,
         shall continue in effect until any and all royalty payment obligations
         of CUBIST shall have expired in accordance with the provisions of
         Section 6.3 hereof. Upon expiration of all royalty payment obligations
         of CUBIST in accordance with the provisions of Section 6.3 hereof, the
         term of this Agreement shall be deemed to have expired.

9.2      TERMINATION BY EITHER PARTY FOR CAUSE. This Agreement may be
         terminated by written notice given by either Party to the otherParty at
         any time during the term of this Agreement:

         (a)  if the other Party is in breach of its material obligations
              hereunder and has not cured such breach within [*] days after
              notice requesting cure of the breach; or

         (b)  upon the filing or institution of bankruptcy, liquidation or
              receivership proceedings, or upon an assignment of a substantial
              portion of the assets for the benefit of creditors by the other
              Party; PROVIDED, HOWEVER, in the case of any involuntary
              bankruptcy proceeding such right to terminate shall only become
              effective if such other Party consents to the involuntary
              bankruptcy or such proceeding is not dismissed within [*] days
              after the filing thereof.

9.3      SPECIAL TERMINATION RIGHTS OF CUBIST. This Agreement may be
         terminated by CUBIST at any time during the term of this Agreement for
         any reason or no reason if CUBIST gives at least [*] days prior written
         notice of termination to BIOCHEMIE.

9.4      SPECIAL TERMINATION RIGHTS OF BIOCHEMIE.

         (a)  In the event that CUBIST breaches its diligence obligation
              under Section 3.6 hereof by not using commercially reasonable
              efforts to research, develop,

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -35-

              promote, market, sell, offer to sell and otherwise commercialize
              at least one Licensed Product in all or some of the Major Market
              Countries (the "DEFAULT MAJOR MARKET COUNTRIES") at any time
              during the term of this Agreement and such breach has not been
              cured within [*] days after BIOCHEMIE gives written notice of such
              breach to CUBIST requesting cure of the breach, then BIOCHEMIE may
              terminate CUBIST's rights under this Agreement (including, without
              limitation, under Section 3.1 hereof) to research, develop,
              promote, market, sell, offer to sell and otherwise commercialize
              Licensed Products in any of the Default Major Market Countries by
              giving written notice to CUBIST specifying the Default Major
              Market Countries as to which BIOCHEMIE is exercising its
              termination right under this Section 9.4., PROVIDED that BIOCHEMIE
              must deliver such notice of termination no later than [*] days
              after the expiration of such [*] day cure period. Upon termination
              by BIOCHEMIE pursuant to this Section 9.4(a) of CUBIST's right to
              research, develop, promote, market, sell, offer to sell and
              otherwise commercialize Licensed Products in any Default Major
              Market Country, neither Party shall have any liability or
              obligation to the other Party under this Agreement with respect to
              such Default Major Market Country, including with respect to
              Article VI, PROVIDED HOWEVER, that termination pursuant to this
              Section 9.4(a) of CUBIST's right under this Agreement with respect
              to such Default Major Market Country shall not relieve CUBIST of
              its obligations under Article VI with respect to such Default
              Major Market Country to the extent that such obligations have
              accrued prior to the effective date of such termination. The
              license granted to CUBIST under Section 3.1 shall terminate with
              respect to such Default Major Market Country. Notwithstanding the
              foregoing, CUBIST shall have the right to sell out in such Default
              Major Market Country all of its inventory of Licensed Products for
              sale in such Default Major Market Country for a period of [*]
              months from the date of termination. CUBIST and BIOCHEMIE hereby
              agree that, upon termination pursuant to this Section 9.4(a) of
              CUBIST's right to research, develop, promote, market, sell, offer
              to sell and otherwise commercialize Licensed Products in any
              Default Major Market Country, the Parties shall discuss mutually
              acceptable actions that the Parties could consider and ultimately
              decide to implement in order to accelerate the exercise by CUBIST
              of its right to sell out in such Default Major Market Country all
              of CUBIST's inventory of Licensed Products for sale in such
              Default Major Market Country.

         (b)  In the event that [*] with respect to [*] for the [*] in
              accordance with [*] or in the event that [*] with respect to [*]
              for the

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -36-

              [*], then [*], PROVIDED that [*]. The [*]. Notwithstanding
              anything expressed or implied in this Section 9.4(b) to the
              contrary, [*] or [*], respectively, specified above in this
              Section 9.4(b) [*], including, but not limited to, [*].

         (c)  In the event that, at any time during the term of this
              Agreement, CUBIST is not researching, developing or
              commercializing any Licensed Products and that CUBIST no longer
              has the right to replace any Abandoned Product with a BIOCHEMIE
              Similar Compound pursuant to Section 3.5(b) hereof, then BIOCHEMIE
              shall have the right to terminate this Agreement by giving [*]
              days' prior written notice of termination to CUBIST, PROVIDED that
              at the time such written notice of termination is given the
              conditions specified in this Section 9.4(c) for the exercise of
              such termination right continue to exist.

9.5      EFFECT OF EXPIRATION OR TERMINATION OF THIS AGREEMENT.

         (a)  In the event that the term of this Agreement expires pursuant
              to Section 9.1 hereof, then this Agreement shall terminate, and,
              except to the extent otherwise provided in this Section 9.5(a) and
              Section 9.5(e) below, neither Party shall have any liability or
              obligation to the other Party under this Agreement, including,
              without limitation, under Article V and Article VI.
              Notwithstanding the foregoing sentence, the licenses granted to
              CUBIST under Article III shall survive such termination and such
              licenses shall be deemed to be fully paid up.

         (b)  In the event that CUBIST terminates this Agreement pursuant to
              Section 9.2, then this Agreement shall terminate, and, except to
              the extent otherwise provided in this Section 9.5(b) and Section
              9.5(e) below, neither Party shall have any liability or obligation
              to the other Party under this Agreement. Notwithstanding the
              foregoing sentence, (i) the rights (but not the obligations) of
              CUBIST, and the obligations (but not the rights) of BIOCHEMIE,
              under Articles II and III (including, without limitation, the
              licenses granted to CUBIST under Article III) shall survive such
              termination and (ii) the rights and obligations of the Parties
              under Article VI shall survive such termination.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -37-

         (c)  In the event that CUBIST terminates this Agreement pursuant to
              Section 9.3, or in the event that BIOCHEMIE terminates this
              Agreement pursuant to Section 9.2, Section 9.4(b) or Section
              9.4(c) hereof, then this Agreement shall terminate, and, except to
              the extent otherwise provided in this Section 9.5(c) and Section
              9.5(e) below, neither Party shall have any liability or obligation
              to the other Party under this Agreement, including with respect to
              Article V and Article VI. The licenses granted to CUBIST under
              Article III shall terminate. Notwithstanding the foregoing, in the
              event that CUBIST terminates this Agreement pursuant to Section
              9.3 or BIOCHEMIE terminates this Agreement pursuant to Section
              9.2, CUBIST shall have the right to sell out in the Territory all
              of its inventory of Licensed Products for a period of [*] months
              from the date of termination. In the event that CUBIST terminates
              this Agreement pursuant to Section 9.3, then, within [*] days
              following the effective date of such termination, [*] either (1)
              to [*] developed by [*] and that are [*] or (2) a [*] of any then
              [*]. If [*] within such [*], it shall [*]. If [*], [*] within [*]
              days after [*].

         (d)  In the event this Agreement is terminated due to the rejection
              of this Agreement by or on behalf of a Party under Section 365 of
              the United States Bankruptcy Code (the "CODE"), all licenses and
              rights to licenses granted under or pursuant to this Agreement by
              one Party to the other are, and shall otherwise be deemed to be,
              for purposes of Section 365(n) of the Code, licenses of rights to
              "intellectual property" as defined under Section 101(35A) of the
              Code. The Parties agree that the licensed Party, as a licensee of
              such rights under this Agreement, shall retain and may fully
              exercise all of its rights and elections under the Code, and that
              upon commencement of a bankruptcy proceeding by or against a Party
              under the Code, the other Party shall be entitled to a complete
              duplicate of or complete access to, any such intellectual property
              and all embodiments of such intellectual property. Such
              intellectual property and all embodiments thereof shall be
              promptly delivered to the other Party (i) upon any such
              commencement of a bankruptcy proceeding upon written request
              therefor by a Party, unless the Party elects to continue to
              perform all of its obligations under this Agreement or (ii) if not
              delivered under (i) above, upon the rejection of this Agreement by
              or on behalf of the Party upon written request therefor. The
              foregoing is without prejudice to any rights either Party may have
              arising under the Code or other applicable law.

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -38-

         (e)  Termination of this Agreement shall not relieve either Party
              of any obligation of such Party accruing prior to such
              termination. Any termination of this Agreement shall be without
              prejudice to the rights of either Party against the other accrued
              or accruing under this Agreement prior to termination. The
              provisions of Article I, Article VII (except with respect to
              Section 7.1.1(c)), Section 8.1, Article IX, X and Article XI shall
              survive the termination of this Agreement. The provisions of
              Article IV shall survive any termination of this Agreement for a
              period of ten (10) years. The provisions of Article VIII (other
              than Section 8.1 above) shall survive the termination of this
              Agreement to the extent necessary to protect CUBIST's rights under
              any licenses granted to CUBIST that survive any such termination
              of this Agreement.

                                    ARTICLE X
                               DISPUTE RESOLUTION

10.1     ESCALATION. The parties shall attempt to resolve any controversy
         or dispute that arises under or relates to this Agreement through good
         faith discussions. The Parties shall initiate such discussions using
         the following procedure. Either Party shall notify the other Party of
         the nature of the controversy or dispute, providing sufficient detail
         to permit the other Party to understand same (a "DISPUTE NOTICE"). The
         representatives of the Parties shall meet within [*] days after the
         date that the non-sending Party receives the Dispute Notice to attempt
         to reach an agreement about the nature of the dispute and a resolution
         of the dispute. If they are unable to resolve the dispute within [*]
         days after their meeting, and do not agree to extend the time period
         for resolving the dispute, or if the terms and conditions of the
         resolution or settlement of the dispute are breached, the dispute shall
         be resolved by arbitration pursuant to the provisions of Section 10.2.
         Pending resolution of any dispute covered by this Section 10.1, both
         Parties will continue their performance under this Agreement including,
         without limitation, the payment of all amounts due to the other Party
         that are not in dispute.

10.2     ARBITRATION.

         (a)  Any claim, dispute, or controversy arising out of or relating
              to this Agreement that is not resolved in accordance with the
              provisions of Section 10.1 and that the Parties agree to submit to
              binding arbitration pursuant to this Section 10.2 will be
              submitted by the parties to arbitration by the International
              Chamber of Commerce ("ICC") under the International
              Arbitration Rules then in effect for the ICC in New York, New York
              U.S.A. ("ICC RULES"), as modified herein or by agreement
              of the parties. Any such arbitration shall be conducted in New
              York, New York by three (3) arbitrators, unless two out of the
              three arbitrators elect to conduct such arbitration in Paris,
              France, in which case such arbitration shall be conducted in
              Paris, France. Each Party shall select one (1) arbitrator and such
              arbitrators shall jointly appoint the third arbitrator who shall
              act as the chairman. If either Party fails to appoint an
              arbitrator within [*] days of a request by the other Party, or if
              the arbitrators selected by the parties cannot agree on a chairman
              within [*] days after they have been selected, then either Party
              may

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -39-

              request the President of the ICC to appoint such co-arbitrator
              (for the non-responsive Party) or the chairman. Such appointment
              shall be binding on the Parties. Each Party irrevocably and
              unconditionally (i) consents to the jurisdiction of any such
              proceeding and waives any objection that it may have to personal
              jurisdiction or the laying of venue of any such proceeding; and
              (ii) knowingly and voluntarily waives its rights to have disputes
              tried and adjudicated by a judge and jury except as otherwise
              expressly provided herein. The Parties will cooperate with each
              other in causing the arbitration to be held in as efficient and
              expeditious a manner as practicable. Unless the Parties agree
              otherwise, they shall be limited in their discovery to directly
              relevant documents. Responses or objections to a document request
              shall be served [*] days after receipt of the request. The
              arbitrators shall resolve any discovery disputes. Nothing herein
              shall prevent the Parties from settling any dispute by mutual
              agreement at any time.

         (b)  The arbitration shall be of each Party's individual claims
              only, and no claim of any other Party shall be subject to
              arbitration in such proceeding. Except as otherwise required by
              law, the Parties and the arbitrator(s) shall maintain as
              confidential all information or documents obtained during the
              arbitration process, including the resolution of the dispute. The
              arbitration shall be conducted in English language.

         (c)  The arbitrator(s) shall not have the authority to award any
              injunctive relief or to award exemplary or punitive damages, and
              the Parties expressly waive any right to such damages. The
              arbitrator(s) shall have the authority to award actual money
              damages (including interest on unpaid amounts from the date due).
              The costs and expenses of the arbitration, but not the costs and
              expenses of the Parties, shall be shared equally by the Parties,
              provided that the non-prevailing Party in any arbitration shall
              pay the other Party's costs and expenses (including travel
              expenses) and reimburse such Party for its portion of the
              arbitration costs. In the event that neither Party wins totally,
              reimbursement shall be made proportionally in accordance with the
              ICC Rules. Any award rendered by the arbitrator(s) shall be final
              and binding upon the Parties. Judgment upon the award may be
              entered in any court of competent jurisdiction. If a Party fails
              to proceed with arbitration, unsuccessfully challenges the
              arbitration award, or fails to comply with the arbitration award,
              the other Party is entitled to costs, including reasonable
              attorneys' fees, for having to compel arbitration or defend or
              enforce the award.

                                   ARTICLE XI
                                  MISCELLANEOUS

11.1     FORCE MAJEURE. Neither Party shall be held liable or responsible
         to the other Party nor be deemed to have defaulted under or breached
         the Agreement for failure or delay in fulfilling or performing any term
         of the Agreement when such failure or delay is caused by or results
         from causes beyond the reasonable control of the affected Party
         including,

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                      -40-

         but not limited to, earthquakes, fire, floods, embargoes,
         insurrections, riots, civil commotions, strikes, lockouts or other
         labor disturbances, acts of God or acts, omissions or delays in acting
         by any governmental authority or the other Party. The affected Party
         shall notify the other Party of such force majeure circumstances as
         soon as reasonably practical.

11.2     ASSIGNMENT. Except as otherwise expressly provided in this Section
         11.2 or elsewhere in this Agreement, this Agreement may not be assigned
         or otherwise transferred, nor may any right or obligation hereunder be
         assigned or transferred, by either Party without the prior written
         consent of the other Party. Either Party may, without the prior written
         consent of the other Party, assign this Agreement and such Party's
         rights and obligations hereunder in connection with the transfer or
         sale of all or substantially all of such Party's assets related to
         Licensed Products or the business, or in the event of its merger or
         consolidation or change in control or similar transaction. Any
         permitted assignee shall assume all obligations of its assignor under
         the Agreement except as otherwise provided herein.

11.3     SEVERABILITY. In the event any one or more of the provisions
         contained in this Agreement should be held invalid, illegal or
         unenforceable in any respect, the validity, legality and enforceability
         of the remaining provisions contained herein shall not in any way be
         affected or impaired thereby, unless the absence of the invalidated
         provision(s) adversely affect the substantive rights of the Parties.
         The Parties shall in such an instance use their best efforts to replace
         the invalid, illegal or unenforceable provision(s) with valid, legal
         and enforceable provision(s) that, insofar as practical, implement the
         purposes of this Agreement.

11.4     NOTICES. All notices or other communications that are required or
         permitted hereunder shall be in writing and sufficient if delivered
         personally, sent by telecopier (and promptly confirmed by personal
         delivery, registered or certified mail or overnight courier), sent by
         nationally-recognized overnight courier or sent by registered or
         certified mail, postage prepaid, return receipt requested, addressed as
         follows:

              if to CUBIST, to:

                                          Cubist Pharmaceuticals, Inc.
                                          65 Hayden Avenue
                                          Lexington, MA  02421
                                          Attention:  President
                                          Telecopier No.: (781) 861-1412

              with a copy to:             Cubist Pharmaceuticals, Inc.
                                          65 Hayden Avenue
                                          Lexington, MA  02421
                                          Attention: General Counsel
                                          Telecopier No.: (781) 861-0566

<Page>

                                      -41-

              also with a copy to:        Bingham McCutchen LLP
                                          150 Federal Street
                                          Boston, MA  02110
                                          Attention: Julio E. Vega, Esq.
                                          Telecopier No.: (617) 951-8736

              if to BIOCHEMIE, to:        Biochemie GmbH
                                          Biochemiestrasse 10
                                          A-6250 Kundl, Austria
                                          Attention: General Counsel
                                          Telecopier No.:  ++43 5338 8828

              with a copy to:             Biochemie GmbH
                                          Brunner Strasse 59
                                          A-1235 Vienna, Austria
                                          Attention: Head Antibiotic Research
                                                      Institute
                                          Telecopier No.: ++43 1 866 34 785

         or to such other address as the Party to whom notice is to be given may
         have furnished to the other Party in writing in accordance herewith.
         Any such communication shall be deemed to have been given when
         delivered if personally delivered or sent by telecopier on a business
         day, on the business day after dispatch if sent by
         nationally-recognized overnight courier and on the third business day
         following the date of mailing if sent by mail.

11.5     APPLICABLE LAW; JURISDICTION; VENUE. The Agreement shall be
         governed by and construed in accordance with the laws of the United
         Kingdom without reference to any rules of conflict of laws. The Parties
         irrevocably consent to the exclusive personal jurisdiction (except as
         to actions for the enforcement of a judgment, in which case such
         jurisdiction shall be non-exclusive) of the federal and state courts
         located in Suffolk County, Massachusetts, and venue in Suffolk County,
         Massachusetts.

11.6     ENTIRE AGREEMENT. The Agreement contains the entire understanding
         of the Parties with respect to the subject matter hereof. All express
         or implied agreements and understandings, either oral or written,
         heretofore made are expressly merged in and made a part of the
         Agreement. Except as expressly set forth in this Agreement, the
         Agreement may be amended, or any term hereof modified, only by a
         written instrument duly executed by both Parties.

11.7     HEADINGS. The captions to the several Articles and Sections hereof
         are not a part of the Agreement, but are merely guides or labels to
         assist in locating and reading the several Articles and Sections
         hereof.

11.8     INDEPENDENT CONTRACTORS. It is expressly agreed that CUBIST and
         BIOCHEMIE shall be independent contractors and that the relationship
         between the two Parties shall not constitute a partnership, joint
         venture or agency. Neither CUBIST nor BIOCHEMIE

<Page>

                                      -42-

         shall have the authority to make any statements, representations or
         commitments of any kind, or to take any action, which shall be binding
         on the other, without the prior consent of the other Party.

11.9     WAIVER. The waiver by either Party hereto of any right hereunder
         or the failure to perform or of a breach by the other Party shall not
         be deemed a waiver of any other right hereunder or of any other breach
         or failure by said other Party whether of a similar nature or
         otherwise.

11.10    COUNTERPARTS. The Agreement may be executed in two or more
         counterparts, each of which shall be deemed an original, but all of
         which together shall constitute one and the same instrument.

11.11    WAIVER OF RULE OF CONSTRUCTION. Each Party has had the
         opportunity to consult with counsel in connection with the review,
         drafting and negotiation of this Agreement. Accordingly, the rule of
         construction that any ambiguity in this Agreement shall be construed
         against the drafting Party shall not apply.

11.12    THIRD PARTY BENEFICIARIES. Except as otherwise expressly provided
         in this Agreement, nothing herein expressed or implied is intended or
         shall be construed to confer upon or to give to any third party any
         rights or remedies by reason of this Agreement. Except as otherwise
         expressly provided in this Agreement, there are no intended third party
         beneficiaries under or by reason of this Agreement.

            [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

<Page>

                                      -43-

     IN WITNESS WHEREOF, the Parties have executed this License Agreement as a
sealed instrument as of the date first set forth above.

BIOCHEMIE GMBH                              CUBIST PHARMACEUTICALS, INC.

By:/s/G. Ascher /s/ J. Gerstenbauer         By:/S/ S.M. Rocklage
  ---------------------------------         ------------------------
Name: G. Ascher     J. Gerstenbauer         Name: Scott M. Rocklage
Title Head ABRI     General Counsel         Title: Chairman and CEO

<Page>

                                   SCHEDULE 1
           (Section 1.9 - BIOCHEMIE Patents as of the Effective Date)

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 2
      (Section 1.13 - BIOCHEMIE Similar Compounds as of the Effective Date)

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 3
 (Section 1.13 - Criteria for BIOCHEMIE Similar Compounds Not Listed on
   SCHEDULE 2)

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 4
                      (Section 1.14 - BIOCHEMIE Trademarks)

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 5
                            (Section 1.19 - Compound)

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 6
                             (Section 5.3(a) - [*])

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

<Page>

                                   SCHEDULE 7
                             (Section 5.3(b) - [*])

[*]

* Confidential Treatment Requested: omitted portions filed with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]